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A B S T R A C T   
Background: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and pre-
vent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. 
Methods: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 
2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta- 
analyses of prevalence. For network meta-analyses we required comparison adjusted funnel plots. We 
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excluded treatment studies with waiting-list or treatment as usual controls. From this literature, we extracted 
evidence-based assertions about the disorder. 
Results: We generated 208 empirically supported statements about ADHD. The status of the included statements 
as empirically supported is approved by 80 authors from 27 countries and 6 continents. The contents of the 
manuscript are endorsed by 366 people who have read this document and agree with its contents. 
Conclusions: Many findings in ADHD are supported by meta-analysis. These allow for firm statements about the 
nature, course, outcome causes, and treatments for disorders that are useful for reducing misconceptions and 
stigma.   
1. Introduction 
Nearly two decades ago, an international team of scientists published 
the first International Consensus Statement on attention-deficit hyper-
activity disorder (ADHD) (Barkley, 2002). They sought to present the 
wealth of scientific data attesting to the validity of ADHD as a mental 
disorder and to correct misconceptions about the disorder that stigma-
tized affected people, reduced the credibility of health care providers, 
and prevented or delayed treatment of individuals challenged by the 
disorder (DosReis et al., 2010; Horton-Salway, 2013; McLeod et al., 
2007; Mueller et al., 2012). 
This paper updates the International Consensus Statement by cata-
loging important scientific discoveries from the last 20 years. We do not 
intend to present an encyclopedia of ADHD or guidelines for diagnosis 
and treatment. The latter can be found in the references cited. Our aim is 
to provide current and accurate information about ADHD supported by a 
substantial and rigorous body of evidence. 
2. Methods 
We identified evidence-based statements about ADHD through 
expert scrutiny of published high quality meta-analyses and very large 
studies. Expert scrutiny was provided by a project Steering Committee 
(Supplemental Table 1) which included representatives from the 
following professional groups dedicated to research and clinical care of 
ADHD: The World Federation of ADHD, EUropean NETwork for Hy-
perkinetic DIsorderS (Eunethydis), the American Professional Society of 
ADHD and Related Disorders, the Canadian ADHD Resource Alliance, 
the Asian Federation of ADHD, the Latin American League of ADHD, the 
Australian ADHD Professionals Association, the Israeli Society of ADHD, 
the Saudi ADHD Society, Neurodevelopmental Disorders Across Life-
span section of the European Psychiatric Association, the ADHD 
Guidelines Group of the Association of Medical Scientific Societies in 
Germany, the ADHD Network of European College of Neuro-
psychopharmacology, the Chinese Society of Child and Adolescent 
Psychiatry and the ADHD Section of the World Psychiatric Association. 
For large cohort studies, we searched PubMed with these search 
criteria: ADHD [tiab] AND (nationwide [tiab] OR national [tiab] OR 
register [tiab] OR registry [tiab]) NOT review [Publication Type] NOT 
meta-analysis [Publication Type]. For meta-analyses, we searched 
PubMed with these search criteria: ADHD [All Fields] AND (meta- 
analysis [Title] OR meta-analysis [Title] OR meta-analytic [Title] OR 
systematic review [Title]). We excluded meta-analyses that did not 
assess publication bias, except for meta-analyses of prevalence. For 
network meta-analyses we required that comparison adjusted funnel 
plots be presented. For treatment studies, we excluded results of meta- 
analyses including comparisons of treatments with waiting-list or 
treatment as usual controls. 
Apart from statements about the history of ADHD and its diagnostic 
criteria, we required each evidence-based statement to be supported by 
meta-analyses or by large registry studies with more than 2000 partic-
ipants. We required meta-analyses to report data from five or more 
studies or 2000 or more participants. 
We describe the magnitude of effect size findings using standard 
criteria as follows: standardized mean difference: small = 0.20, 
medium = 0.50, large = 0.80; correlation coefficient: small = 0.10, me-
dium = 0.24, large = 0.37 (Ellis, 2010; Rosenthal and Rosnow, 1984). 
“Moderate” is used as a synonym for “medium,” and “strong” for “large.” 
A “small” effect is generally difficult to observe in an individual but may 
be very important for public health if it concerns a common exposure 
that affects many children. A “medium” effect is expected to be 
noticeable to a careful observer (Cohen, 1988). A “large” effect is 
generally relevant to clinical practice at the level of the individual. 
If a topic is not included in this document, it does not mean the topic 
is unimportant; rather, it means the evidence found was insufficient to 
allow firm conclusions. This could be because there were insufficient 
studies of quality, because no attempt was made to assess publication 
bias, or because the data available did not support the claims made. 
After the document was completed, we invited additional colleagues to 
join as signatories to indicate their support of the document. In what 
Table 1 
Summary of Findings.  
Findings Items 
The syndrome we now call ADHD has been described in the medical 
literature since 1775. 
1–13 
When made by a licensed clinician, the diagnosis of ADHD is well-defined 
and valid at all ages, even in the presence of other psychiatric 
disorders, which is common. 
14–19 
ADHD is more common in males and occurs in 5.9 % of youth and 2.5 % 
of adults. It has been found in studies from Europe, Scandinavia, 
Australia, Asia, the Middle East, South America, and North America. 
20–25 
ADHD is rarely caused by a single genetic or environmental risk factor 
but most cases of ADHD are caused by the combined effects of many 
genetic and environmental risks each having a very small effect. 
26–62 
People with ADHD often show impaired performance on psychological 
tests of brain functioning, but these tests cannot be used to diagnose 
ADHD. 
63–70 
Neuroimaging studies find small differences in the structure and 
functioning of the brain between people with and without ADHD. 
These differences cannot be used to diagnose ADHD. 
71–77 
People with ADHD are at increased risk for obesity, asthma, allergies, 
diabetes mellitus, hypertension, sleep problems, psoriasis, epilepsy, 
sexually transmitted infections, abnormalities of the eye, immune 
disorders, and metabolic disorders. 
78–100 
People with ADHD are at increased risk for low quality of life, substance 
use disorders, accidental injuries, educational underachievement, 
unemployment, gambling, teenage pregnancy, difficulties socializing, 
delinquency, suicide, and premature death. 
101–136 
Studies of economic burden show that ADHD costs society hundreds of 
billions of dollars each year, worldwide. 
137–147 
Regulatory agencies around the world have determined that several 
medications are safe and effective for reducing the symptoms of ADHD 
as shown by randomized controlled clinical trials. 
148–157 
Treatment with ADHD medications reduces accidental injuries, 
traumatic brain injury, substance abuse, cigarette smoking, 
educational underachievement, bone fractures, sexually transmitted 
infections, depression, suicide, criminal activity and teenage 
pregnancy. 
158–177 
The adverse effects of medications for ADHD are typically mild and can 
be addressed by changing the dose or the medication. 
178–188 
The stimulant medications for ADHD are more effective than non- 
stimulant medications but are also more likely to be diverted, misused, 
and abused. 
189–194 
Non-medication treatments for ADHD are less effective than medication 
treatments for ADHD symptoms, but are frequently useful to help 
problems that remain after medication has been optimized. 
195–208  
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follows, we use the term "evidence-based" to refer to evidence that meets 
the inclusion/exclusion criteria we used in our literature search. We 
recognize that other criteria could be applied, such as requiring the 
absence of severe heterogeneity in meta-analyses or increasing the 
numbers of research participants. 
3. Overview of results 
Our search strategy generated 208 empirically supported statements 
about ADHD. For details, see the PRISMA diagram in Supplemental 
Figure 1. The status of the included statements as empirically supported 
has been approved by the 80 authors from 27 countries and 6 continents 
(Supplemental Figure 2). It has been endorsed by 366 people who have 
read this document and agree with its contents (Supplemental Table 2). 
Table 1 summarizes our findings along with the item numbers that 
support each statement. A limitation of this consensus statement is that 
we do not report well-established research findings for which meta- 
analyses or very large studies do not exist. The absence of such a 
study is not always an indication of knowledge of absence of an effect. 
4. A Brief history: ADHD is not a new disorder 
The concept of ADHD has a long history, starting with clinical reports 
from European countries. The clinical significance of the signs and 
symptoms of the disorder has been recognized for over two centuries. 
Although these early reports did not use the term “ADHD”, they 
described children who showed the symptoms and impairments we now 
recognize as ADHD. For a detailed history see (Lange et al., 2010; 
Taylor, 2011; Weikard, 1799). Here are highlights from the early history 
of ADHD:  
1 1775: Melchior Adam Weikard, a German physician, wrote the 
first textbook description of a disorder with the hallmarks of 
ADHD.  
2 1798: Alexander Crichton from the Royal College of Physicians 
(United Kingdom) described a similar disorder in a medical 
textbook (Palmer and Finger, 2001).  
3 1845: Heinrich Hoffmann, who later became head of the first 
psychiatric hospital in Frankfurt am Main, Germany, described 
hyperactivity and attention deficits in a children’s book which 
documented ADHD-like behaviors and their associated impair-
ments (Hoffmann, 1990).  
4 1887-1901: Désiré-Magloire Bourneville, Charles Boulanger, 
Georges Paul-Boncour, and Jean Philippe described an equivalent 
of ADHD in French medical and educational writings (Marti-
nez-Badia and Martinez-Raga, 2015).  
5 1902: George Still, a physician in the United Kingdom, wrote the 
first description of the disorder in a scientific journal (Still, 
1902a, b, c).  
6 1907: Augusto Vidal Perera wrote the first Spanish compendium 
of child psychiatry. He described the impact of inattention and 
hyperactivity among schoolchildren (Vidal Perera, 1907).  
7 1917: the Spanish neurologist and psychiatrist Gonzalo 
Rodriguez-Lafora described symptoms of ADHD in children and 
said they were probably caused by a brain disorder with genetic 
origins (Lafora, 1917).  
8 1932: Franz Kramer and Hans Pollnow, from Germany, described 
an ADHD-like syndrome and coined the term “hyperkinetic dis-
order”, which was later adopted as a term by the World Health 
Organization (Kramer and Pollnow, 1932; Neumarker, 2005).  
9 1937: Charles Bradley, from the USA, discovered that an 
amphetamine medication reduced ADHD-like symptoms (Brad-
ley, 1937).  
10 1940s: ADHD-like symptoms in children described as “minimal 
brain dysfunction”.  
11 1956–1958: First hint in follow-up study of the persistence of 
minimal brain dysfunction-related behaviors into adulthood 
(Morris et al., 1956; O’Neal and Robins, 1958) 
12 1960s: U.S. Food and Drug Administration approved methyl-
phenidate (Ritalin) for behavioral disorders in children.  
13 1970s to today: Diagnostic criteria for ADHD evolved based on 
research showing that the diagnosis predicts treatment response, 
clinical course, and family history of the disorder. 
5. How is ADHD diagnosed? 
ADHD can only be diagnosed by a licensed clinician who interviews 
the parent or caregiver and/or patient to document criteria for the dis-
order (American Psychiatric Association, 2013; Chinese Society of Psy-
chiatry, 2001; Faraone et al., 2015; Feldman and Reiff, 2014; Pearl et al., 
2001; Stein, 2008; World Health Organization, 2018). It cannot be 
diagnosed by rating scales alone, neuropsychological tests, or methods 
for imaging the brain. 
The diagnosis of ADHD has been criticized as being subjective 
because it is not based on a biological test. This criticism is unfounded. 
ADHD meets standard criteria for validity of a mental disorder estab-
lished by Robins and Guze (Faraone, 2005; 1970). The disorder is 
considered valid because: 1) well-trained professionals in a variety of 
settings and cultures agree on its presence or absence using well-defined 
criteria and 2) the diagnosis is useful for predicting a) additional prob-
lems the patient may have (e.g., difficulties learning in school); b) future 
patient outcomes (e.g., risk for future drug abuse); c) response to 
treatment (e.g., medications and psychological treatments); and d) 
features that indicate a consistent set of causes for the disorder (e.g., 
findings from genetics or brain imaging) (Faraone, 2005). Professional 
associations have endorsed and published guidelines for diagnosing 
ADHD (Alliance, 2011; Banaschewski et al., 2018; Bolea-Alamanac 
et al., 2014; Crunelle et al., 2018; Flisher and Hawkridge, 2013; Graham 
et al., 2011; Kooij et al., 2019; National Collaborating Centre for Mental 
Health, 2018; National Institute for Health Care and Excellence, 2018a, 
b; Pliszka, 2007; Schoeman and Liebenberg, 2017; Seixas et al., 2012; 
Taylor et al., 2004; Wolraich et al., 2011). 
The main features of the diagnosis are:  
14 The diagnosis requires: 1) the presence of developmentally 
inappropriate levels of hyperactive-impulsive and/or inattentive 
symptoms for at least 6 months; 2) symptoms occurring in 
different settings (e.g., home and school); 3) symptoms that cause 
impairments in living; 4) some of the symptoms and impairments 
first occurred in early to mid-childhood; and 4) no other disorder 
better explains the symptoms (American Psychiatric Association, 
2013; World Health Organization, 2018; Yi and Jing, 2015).  
15 The clinical presentation of ADHD can be described as primarily 
inattentive, primarily hyperactive-impulsive, or combined, 
depending on the nature of their symptoms (American Psychiat-
ric Association, 2013). Meta-analyses indicate that inattention is 
more strongly associated with academic impairment, low 
self-esteem, negative occupational outcomes, and lower overall 
adaptive functioning. Hyperactive-impulsive symptoms are 
associated with peer rejection, aggression, risky driving behav-
iors, and accidental injuries. Patterns of associated disorders also 
differ between the dimensions (Willcutt et al., 2012).  
16 ADHD impairs the functioning of highly intelligent people, so the 
disorder can be diagnosed in this group. A population-based birth 
cohort study of over 5700 children found no significant differ-
ences among children with high, average, or low IQ and ADHD in 
median age at which ADHD criteria were met, rates of learning 
disorders, psychiatric disorders, and substance abuse, and rates of 
stimulant treatment (Katusic et al., 2011; Rommelse et al., 2017).  
17 In adolescence and young adulthood, many individuals with a 
history of childhood ADHD continue to be impaired by the 
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disorder, although they often show reduced hyperactivity and 
impulsivity while retaining symptoms of inattention (Faraone 
et al., 2006).  
18 Many large epidemiologic and clinical studies show that ADHD 
often co-occurs with other psychiatric disorders, especially 
depression, bipolar disorder, autism spectrum disorders, anxiety 
disorders, oppositional defiant disorder, conduct disorder, eating 
disorders, and substance use disorders (Bernardi et al., 2012; 
Chen et al., 2018c; Groenman et al., 2017; Nazar et al., 2016; 
Solberg et al., 2018; Tung et al., 2016; Yao et al., 2019). Their 
presence does not rule out a diagnosis of ADHD.  
19 A meta-analysis comprising 25 studies with over eight million 
participants found that children and adolescents who are rela-
tively younger than their classmates are more likely to have been 
diagnosed with ADHD (Caye et al., 2020) 
6. How common is ADHD? 
ADHD occurs throughout the developed and developing world and is 
more common in males compared with females. It has not become 
more common over the past three decades although due to increased 
recognition by clinicians, the disorder is more likely to be diagnosed 
today than in prior decades.   
20 A meta-analysis of 19 studies with over 55,000 participants found 
that 5.9 % of youths meet diagnostic criteria for ADHD (Willcutt, 
2012). Another meta-analysis, with 135 studies and about a 
quarter of a million youths, found no significant differences in 
prevalence between North America and Europe, Asia, Africa, 
South America, and Oceania (Polanczyk et al., 2014).  
21 The latter meta-analysis found no increase in the prevalence of 
ADHD in children and adolescents over the past three decades 
(Polanczyk et al., 2014). Although the prevalence of ADHD has 
not changed in this time period, large studies from the U.S. and 
Sweden indicate that ADHD is more likely to have been diag-
nosed in recent years, which reflects changes in administrative 
and clinical practices (Rydell et al., 2018; Song et al., 2019; Xu 
et al., 2018). 
22 A meta-analysis of six studies with over 5300 participants esti-
mated the prevalence of ADHD in adulthood to be 2.5 % (Simon 
et al., 2009). A meta-analysis of 20 studies encompassing 13 
countries and seven regions/metropolitan areas, involving more 
than 26,000 participants, estimated that 2.8 % of adults meet 
criteria for ADHD (Fayyad et al., 2017). The lower prevalence in 
adults compared with youths is consistent with a meta-analysis of 
21 studies with over 1600 participants showing that only about 
one in six youths with ADHD still meet full diagnostic criteria for 
ADHD at age 25, and about half show signs of residual impair-
ment (Faraone et al., 2006).  
23 A meta-analysis of nine studies with a total of over 32,000 older 
adults found a prevalence of 2.2 % based on ADHD rating scales, 
dropping to 1.5 % when limited to persons at least fifty years old. 
Yet a meta-analysis of seven studies with over 11.7 million par-
ticipants based on ADHD clinical diagnoses, performed by the 
same team, reported a prevalence of only 0.2 % for persons at 
least fifty years old. A third meta-analysis performed by the same 
researchers, of four studies with over 9.2 million participants, 
found an ADHD treatment rate of only 0.02 % among persons at 
least fifty years old (Dobrosavljevic et al., 2020).  
24 A meta-analysis of 19 studies encompassing over 150,000 U.S. 
Black youths under 18 years old reported an ADHD prevalence 
rate of 14 %. The authors concluded, "Black individuals are at 
higher risk for ADHD diagnoses than the general US population. 
These results highlight a need to increase ADHD assessment and 
monitoring among Black individuals from different social back-
grounds" (Cénat et al., 2021). 
25 ADHD is more common in males. A meta-analysis of parent rat-
ings of symptoms in 29 studies with over 42,000 participants, and 
teacher ratings in 24 studies with over 56,000 participants, found 
a roughly two-to-one male/female ratio in youth (Willcutt, 
2012). 
7. What causes ADHD? 
For most people with ADHD, many genetic and environmental risk 
factors accumulate to cause the disorder (Faraone et al., 2015). The 
environmental risks for ADHD exert their effects very early in life, 
during the fetal or early postnatal period. In rare cases, however, 
ADHD-like symptoms can be caused by extreme deprivation early in life 
(Kennedy et al., 2016), a single genetic abnormality (Faraone and 
Larsson, 2018), or traumatic brain injury early in life (Stojanovski et al., 
2019). These findings are helpful to understand the causes of ADHD but 
are not useful for diagnosing the disorder. The associations between 
aspects of the environment and the onset of ADHD have attained a very 
high level of evidential support. Some have strong evidence for a causal 
role but, for most, the possibility remains that these associations are due 
to correlated genetic and environmental effects. For this reason, we refer 
to features of the pre- and post-natal environments that increase risk for 
ADHD as correlates, rather than causes. The genetic and environmental 
risks described below are not necessarily specific to ADHD. 
7.1. Genetic causes of ADHD  
26 A review of 37 twin studies from the United States, Europe, 
Scandinavia, and Australia found that genes and their interaction 
with the environment must play a substantial role in causing 
ADHD (Faraone and Larsson, 2018; Larsson et al., 2014a; Pet-
tersson et al., 2019).  
27 In a genomewide study, an international team analyzed DNA 
from over 20,000 people with ADHD and over 35,000 without 
ADHD from the United States, Europe, Scandinavia, China, and 
Australia. They identified many genetic risk variants, each having 
a small effect on the risk for the disorder (Demontis et al., 2019). 
This study confirmed a polygenic cause for most cases of ADHD, 
meaning that many genetic variants, each having a very small 
effect, combine to increase risk for the disorder. The polygenic 
risk for ADHD is associated with general psychopathology (Bri-
kell et al., 2020) and several psychiatric disorders (Lee et al., 
2019a,b).  
28 Additional genes have been implicated by meta-analyses, but 
their status as risk genes remains uncertain until validated in a 
genomewide study. These genes are ANKK1 (Pan et al., 2015) 
DAT1 (Grunblatt et al., 2019b), LRP5 and LRP6 (Grunblatt et al., 
2019a), SNAP25 (Liu et al., 2017b), ADGRL3 (Bruxel et al., 2020) 
DRD4 and BAIAP2 (Bonvicini et al., 2020, 2016).  
29 The polygenic risk for ADHD predicts ADHD symptoms in the 
population, suggesting that the genetic causes of ADHD as a 
disorder also influence sub-threshold levels of ADHD symptoms 
in the population (Demontis et al., 2019; Taylor et al., 2019).  
30 In the population, those with a high polygenic risk for ADHD are 
more likely to have been diagnosed with ADHD (Li, 2019), anx-
iety, or depression (Martin et al., 2018).  
31 ADHD can also be the result of rare single gene defects (Faraone 
and Larsson, 2018) or abnormalities of the chromosomes 
(Cederlof et al., 2014). When the DNA of 8000+ children with 
autism spectrum disorder (ASD) and/or ADHD and 5000 controls 
was analyzed, those with ASD and those with ADHD had an 
increased rate of rare genetic mutations compared with controls 
(Satterstrom et al., 2019). 
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32 Family, twin, and DNA studies show that genetic and environ-
mental influences are partially shared between ADHD and many 
other psychiatric disorders (e.g. schizophrenia, depression, bi-
polar disorder, autism spectrum disorder, conduct disorder, 
eating disorders, and substance use disorders) and with somatic 
disorders (e.g. migraine and obesity) (Demontis et al., 2019) 
(Faraone and Larsson, 2018) (Ghirardi et al., 2018) (Lee et al., 
2019a,b) (Lee et al., 2013) (Anttila et al., 2018; Tylee et al., 2018) 
(van Hulzen et al., 2017) (Vink and Schellekens, 2018) (Brikell 
et al., 2018) (Chen et al., 2019a) (Yao et al., 2019). However, 
there is also a unique genetic risk for ADHD. Evidence of shared 
genetic and environmental risks among disorders suggest that 
these disorders also share a pathophysiology in the biological 
pathways that dysregulate neurodevelopment and create brain 
variations leading to disorder onset.  
33 Very large studies of families suggest that ADHD shares genetic or 
familial causes with autoimmune diseases (Li et al., 2019), 
hypospadias (Butwicka et al., 2015), and intellectual disability 
(Faraone and Larsson, 2018). 
7.2. Environmental correlates of ADHD: exposure to toxicants  
34 A pair of meta-analyses found small correlations between lead 
burden and inattention symptoms (27 studies, over 9300 youths) 
and hyperactivity-impulsivity symptoms (23 studies, over 7800 
youths) (Goodlad et al., 2013). A more recent meta-analysis of 14 
studies with over 17,000 children reported that higher blood lead 
levels were associated with quadrupled odds of ADHD (Nilsen 
and Tulve, 2020). A study of over 2500 youths from the National 
Health and Nutrition Examination Survey, a cross-sectional, na-
tionally representative sample of the U.S. population, found that 
those with blood lead levels in the top third were 2.3 times more 
likely to have ADHD compared with those in the bottom third 
(Froehlich et al., 2009). A similar study, with over 4700 youths 
from the same national survey, found that those with blood lead 
levels in the highest fifth were four times more likely to have 
ADHD compared with those in the bottom fifth (Braun et al., 
2006).  
35 Three meta-analyses with over twenty studies covering more than 
three million persons have found prenatal exposure to maternal 
smoking associated with a greater than 50 % increase in inci-
dence of ADHD (Huang et al., 2018a) (Dong et al., 2018; Nilsen 
and Tulve, 2020). Although this association has also been seen in 
large population studies (Joelsson et al., 2016; Obel et al., 2016; 
Skoglund et al., 2014), it disappears after adjusting for family 
history of ADHD, which indicates that the association between 
maternal smoking during pregnancy and ADHD is due to familial 
or genetic factors that increase the risk for both smoking and 
ADHD.  
36 A meta-analysis of nine studies spanning three continents and 
over 100,000 participants found that childhood exposure to 
secondhand cigarette smoke was associated with a 60 % greater 
likelihood of ADHD. It was unclear to what extent the association 
was causal versus due to confounders (Huang et al., 2021).  
37 In a meta-analysis of 15 double-blind, placebo-controlled trials 
with 219 participants, artificial food dyes were associated with a 
small increase in hyperactivity in children (Schab and Trinh, 
2004). Another meta-analysis, covering 20 studies with a com-
bined total of 794 individuals, found a very small increase in 
ADHD symptoms, but only when rated by parents, not by teachers 
or other observers (Nigg et al., 2012).  
38 In a Taiwanese study of over 10,000 births, maternal use of 
acetaminophen during pregnancy was associated with a 33 % 
greater likelihood of ADHD in their children (Chen et al., 2019b). 
Another study, examining 113,000 offspring from the Norwegian 
Mother and Child Cohort Study and the Norwegian Patient 
Registry, including 2246 with ADHD, found a dose-response 
relationship between maternal prenatal use of acetaminophen 
and ADHD (Ystrom et al., 2017).  
39 A nationwide study using the Danish national registers looked at 
913,000 children born between 1997 and 2011. Prenatal expo-
sure to the anti-epileptic drug valproate was associated with a 50 
% greater risk of ADHD. No associations were found for other 
anti-epileptic drugs (Christensen et al., 2019).  
40 In a Norwegian registry study, 297 children with ADHD and 553 
controls were randomly sampled from an eligible population of 
over 24,000. Children of mothers in the highest quintile of 
phthalate metabolite levels were three times more likely to have 
had ADHD as children compared with those in the bottom quin-
tile, after adjusting for confounders, such as maternal age at de-
livery, sex of the child, maternal education, marital status, and 
prenatal maternal smoking (Engel et al., 2018).  
41 Organophosphate pesticides are potent neurotoxins. In a sample 
of 1139 children from the U.S. population, a tenfold increase in 
the organophosphate metabolite dimethyl alkylphosphate 
(DMAP) was associated with 55 % increase in the probability of 
having ADHD. Children with detectable levels of the most- 
commonly detected DMAP metabolite were twice as likely to 
have ADHD compared with those with undetectable levels 
(Bouchard et al., 2010).  
42 A meta-analysis found no significant effect of two classes of air 
pollutants – particulate matter (six studies, over 51,000 persons) 
and nitrogen oxides (five studies, over 51,000 persons) (Zhang 
et al., 2020b). A Taiwan-wide longitudinal cohort study geo-
linking over 16,000 mother-infant pairs to levels of air pollutants 
found no association between small particulate matter levels, 
sulphur dioxide levels, or nitrogen dioxide levels during gestation 
and ADHD diagnoses in the first eight years of their offsprings’ 
lives. It did find 25 % greater odds for having ADHD with expo-
sures to nitric oxide, a common traffic pollutant (Shih et al., 
2020).  
43 A nationwide cohort study used the South Korean national health 
insurance registry to identify all 7200 hospital admissions of 
adolescents with a primary diagnosis of ADHD from 2013 to 
2015, and daily readings of three air pollutants from 318 moni-
toring stations distributed across the country over the same 
period. It found that spikes in nitrogen dioxide, sulphur dioxide, 
and particulate matter were associated, respectively, with 47 %, 
27 %, and 12 % increases in ADHD related hospital admissions in 
succeeding days. There were no significant differences between 
male and female adolescents, or between older and younger ad-
olescents (Park et al., 2020). 
44 A meta-analysis of nine European population studies encom-
passing 4826 mother-child pairs examined the relationship be-
tween exposure to Perfluoroalkyl Substances (PFAS) via breast 
milk in infancy and development of ADHD. No associations were 
found with ADHD in offspring (Forns et al., 2020).  
45 A meta-analysis of seven studies encompassing a total of over 
25,000 participants from six countries on three continents found 
no evidence of an association between sugar consumption and 
ADHD in youth (Farsad-Naeimi et al., 2020) 
7.3. Environmental correlates of ADHD: nutrient deficiencies  
46 A pair of meta-analyses found no difference in serum iron levels 
in youths with ADHD (six studies, 617 participants) but small-to- 
moderate reductions in serum ferritin, a protein that stores iron 
(ten studies, over 2100 participants) (Wang et al., 2017). Another 
pair of meta-analyses likewise found no difference in serum iron 
levels (six studies, over 1700 participants) but small-to-moderate 
reductions in serum ferritin (12 studies, over 6000 participants) 
(Tseng et al., 2018). 
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47 A meta-analysis of nine studies and 586 people found moderately 
lower overall blood levels of omega-3 PUFAs in ADHD than non- 
ADHD youth (Hawkey and Nigg, 2014).  
48 A nationwide population-based case-control study using the 
Finnish national registers compared 1067 patients with ADHD 
born between 1998 and 1999 with 1067 matched controls. Lower 
maternal vitamin D levels were associated with a roughly 50 % 
greater likelihood of ADHD in their children (Sucksdorff et al., 
2021). 
7.4. Environmental correlates of ADHD: events during pregnancy and 
birth  
49 A meta-analysis of twelve studies with over 6000 participants 
found a threefold increase in the rate of ADHD among very/ 
extremely preterm or very/extremely low birth weight babies 
(Franz et al., 2018). Another meta-analysis, combining 85 studies 
with a total of over 4.6 million births, found a small-to-moderate 
correlation between low birth weight and ADHD (Momany et al., 
2018). A Swedish national register study of 1.2 million children 
found a stepwise increase in the likelihood of ADHD with 
increasing prematurity. Results were not due to having an ADHD 
relative or socioeconomic stress (Lindstrom et al., 2011). Similar 
results were reported from the Finnish national registers when 
comparing over 10,000 people with ADHD with over 38,000 
controls (Sucksdorff et al., 2015).  
50 A meta-analysis of six studies combining 1.4 million people found 
that children whose mothers had hypertensive disorders during 
pregnancy had a 25 % increase in the rate of ADHD (Maher et al., 
2018). 
51 A nationwide population-based cohort study using Swedish reg-
isters and covering more than two million children, 115,000 of 
them with ADHD, found that maternal preeclampsia during 
pregnancy is associated with a 15 % greater subsequent likeli-
hood of ADHD in offspring, rising to over 40 % when the fetus is 
small for gestational age and exposed to preeclampsia. This 
pattern in families showed that it is not due to genetic or other 
family influences (Maher et al., 2020).  
52 Two meta-analyses, one with seven studies with over 28,000 
participants and another with three studies and over 1.4 million 
participants, found that children of obese mothers were roughly 
60 % more likely to develop ADHD (Jenabi et al., 2019; Sanchez 
et al., 2018). A study of over 80,000 mother-child pairs partici-
pating in the Danish National Birth Cohort reported an almost 50 
% elevated risk of ADHD in children of obese mothers and a 
doubled risk in children of severely obese mothers (Andersen 
et al., 2018).  
53 A meta-analysis of two large cohort studies with a combined total 
of over 3.1 million persons found a slight but significant associ-
ation between maternal hyperthyroidism during pregnancy and 
ADHD in offspring. A second meta-analysis of four cohort studies 
encompassing over 3.4 million participants likewise found a 
slight but significant association between maternal hypothy-
roidism and ADHD in offspring. No attempt was made to assess 
the role of confounders (Ge et al., 2020).  
54 A nationwide cohort study using Danish national registers 
examined over a million births, comparing offspring of mothers 
with a single prior miscarriage and mothers with more than one 
prior miscarriage with mothers with no history of miscarriage. It 
found that after adjusting for a wide range of possible con-
founders which turned out to have little effect, children of 
mothers with a single prior miscarriage were 9 % more likely to 
develop ADHD than those of mothers without any miscarriage. 
Children of mothers with two or more prior miscarriages were 22 
% more likely to be diagnosed with ADHD. This upward 
exposure-response trend was statistically significant (Wang et al., 
2020). 
7.5. Environmental correlates of ADHD: deprivation, stress, infection, 
poverty and trauma  
55 A Taiwan-wide longitudinal cohort study based on the country’s 
universal coverage National Health Insurance Research Database 
compared over 14,000 enterovirus patients (ER71) with an equal 
number of controls matched by age and sex. After further 
adjusting for paternal occupation and urbanization level of resi-
dence it found the enterovirus patients were 25 percent more 
likely to subsequently be diagnosed with ADHD (Tseng et al., 
2020). 
56 A nationwide population-based cohort study using Danish regis-
ters compared over 29,000 children born to women who lost a 
close relative during pregnancy with a million other children in 
the same cohort and found that boys born to these women were 
twice as likely to have ADHD (Li et al., 2010).  
57 A U.S. population-based study of over 14,000 participants in the 
National Longitudinal Study of Adolescent Health found that 
after adjusting for demographic, socioeconomic, and familial risk 
factors for child maltreatment, ADHD inattentive type was asso-
ciated with having been exposed to sexual abuse and physical 
neglect (Ouyang et al., 2008).  
58 A nationwide population-based cohort study of over 18,000 
children from the South Korean National Health Insurance 
database found that lower levels of family income were associ-
ated with increased rates of ADHD (Choi et al., 2017). A Swedish 
study of over 800,000 people reported similar results even after 
adjusting for shared familial/genetic risk factors in families 
(Larsson et al., 2014b).  
59 A Danish national register longitudinal cohort study of a million 
people found that Rutter’s indicators of adversity were predictive 
of ADHD. Out-of-home care was strongly predictive; low social 
class, paternal criminality, maternal mental disorder, and severe 
marital discord were moderately predictive. Large family size had 
no effect (Ostergaard et al., 2016).  
60 A countrywide population study using Danish national registers 
looked at over 630,000 youths and found dose-response re-
lationships between lower parental educational attainment, 
parental unemployment, and parental relative poverty and 
higher risk of ADHD in offspring. Combinations of social disad-
vantages had cumulative risks. For instance, parental relative 
income poverty plus completion of no more than compulsory 
education plus unemployment was associated with a roughly five 
percent higher risk of ADHD in their offspring (Keilow et al., 
2020).  
61 A Swedish national register cohort study of over 540,000 people 
found a dose-response relationship between cumulative in-
dicators of adversity in the family and ADHD. A death in the 
family increased the subsequent likelihood of ADHD by 60 %. 
Substantial parental substance abuse, criminality, or psychiatric 
disorder each more than doubled the likelihood as did residential 
instability and household public assistance (Bjorkenstam et al., 
2018).  
62 In a sample of 4122 U.S. youths with ADHD from the 2016 U.S. 
National Survey of Children’s Health, greater family cohesion 
and community support decreased the risk for moderate to severe 
ADHD (Duh-Leong et al., 2020). 
8. What have we learned from studying the brains of people 
with ADHD? 
There are two broad classes of research findings about the brains of 
people with ADHD. The first comes from studies of the performance of 
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patients on psychological tests that study mental processes. The second 
comes from methods that directly examine brain structure or function 
with neuroimaging scans. Although many of these studies have found 
differences between groups of people who are and are not diagnosed 
with ADHD, the differences are typically small and do not dramatically 
differ between people with ADHD and those with other disorders. They 
are, therefore, not useful for diagnosing the disorder (Thome et al., 
2012). These differences are not caused by drug treatment and, for some 
patients, diminish or change as patients grow out of the disorder. 
8.1. Performance deficits in psychological processes  
63 A meta-analysis of 137 studies with over 9400 participants of all 
ages found ADHD to be associated with moderately lower IQ and 
reading scores and larger decreases in spelling and arithmetic 
scores (Frazier et al., 2004). Another meta-analysis, spanning 21 
studies with over 1900 adults, concluded that ADHD-associated 
IQ deficits were small and not clinically meaningful (Bridgett 
and Walker, 2006).  
64 A series of meta-analyses found that people with ADHD had small 
to moderate difficulties with abstract problem solving and 
working memory (12 studies, 952 persons), focused attention (22 
studies, 1493 persons), sustained attention (13 studies, 963 per-
sons), and verbal memory (8 studies, 546 persons) (Schoechlin 
and Engel, 2005). Another meta-analysis, with 11 studies with 
829 participants, reported people with ADHD were moderately 
more prone to cognitive errors known as “rule violations” (Patros 
et al., 2019). 
65 Two meta-analyses, one with 21 studies and over 3900 partici-
pants, the other with 15 studies with over a thousand partici-
pants, found that those diagnosed with ADHD have a moderate 
tendency to favor small immediate rewards over large delayed 
rewards (Jackson and MacKillop, 2016; Marx et al., 2021).  
66 A meta-analysis of 37 studies with more than 2300 participants 
found a small-to-moderate association between ADHD and risky 
decision-making (Dekkers et al., 2016). Another meta-analysis, 
combining 22 studies with 3850 children and adolescents, 
found those with ADHD exhibited moderately greater impulsive 
decision-making overall on delay discounting and delay of grat-
ification tasks (Patros et al., 2016). 
67 A recent meta-meta-analysis included 34 meta-analyses of neu-
rocognitive profiles in ADHD (all ages) concerning 12 neuro-
cognitive domains. Those with ADHD had moderate impairments 
in multiple domains (working memory, reaction time variability, 
response inhibition, intelligence/achievement, planning/organi-
zation). Effects were larger in children and adolescents than in 
adults (Pievsky and McGrath, 2018). 
68 A meta-analysis of 49 studies and over 8200 children and ado-
lescents found moderate impairments in working memory in 
those with ADHD. These deficits declined with age (Ramos et al., 
2020).  
69 Among youths with ADHD, a series of meta-analyses found no 
significant sex differences in either total ADHD symptoms (15, 
studies, over 3400 youths), inattention symptoms (26 studies, 
over 5900 youths), or hyperactivity-impulsivity symptoms (24 
studies, over 4900 youths) (Loyer Carbonneau et al., 2020).  
70 A meta-analysis of randomized controlled trials (RCTs) with 
preschoolers found that cognitive training led to moderate 
improvement in working memory (23 studies, over 2000 partic-
ipants) and small-to-moderate improvement in inhibitory control 
(26 studies, over 2200 participants) (Pauli-Pott et al., 2020). 
8.2. Differences in the brain found by neuroimaging studies  
71 An analysis of structural magnetic resonance imaging (MRI) data 
from 36 cohorts with a total of over 4100 participants found 
slightly reduced total cortical surface area in children with 
ADHD. The same team found some subcortical regions of the 
brain were smaller in children with ADHD, mainly in frontal, 
cingulate, and temporal regions with some reductions in cortical 
thickness in temporal regions. The same team found some 
subcortical regions of the brain, i.e., basal ganglia, amygdala, 
hippocampus, and intracranial volumes were smaller in children 
with ADHD in 23 cohorts of 3242 participants. The differences 
seen in children were not seen in adolescents or adults (Hoogman 
et al., 2017, 2019). All of the differences observed were small to 
very small and subtle.  
72 Comparative meta-analyses show that structural grey matter 
volume reductions in basal ganglia and insula are disorder- 
specific relative to OCD in 30 data sets with 1870 participants 
(Norman et al., 2016) while medial frontal reductions were spe-
cific to ASD in 66 data sets with 3610 participants (Lukito et al., 
2020). An analysis of structural magnetic resonance imaging 
(MRI) data from 48 cohorts with a total of over 12,000 partici-
pants showed that ADHD participants had smaller hippocampus 
volume relative to OCD which was related to IQ differences and 
smaller intracranial volume relative to ASD and OCD patients 
(Boedhoe et al., 2020). The functional under-activations in right 
inferior frontal cortex and basal ganglia during tasks of cognitive 
control were disorder-specific relative to OCD in 1870 partici-
pants (Norman et al., 2016), while the inferior frontal dysfunc-
tion was specific relative to autism in 3610 participants (Lukito 
et al., 2020).  
73 A meta-analysis of ten diffusion tensor imaging studies with 947 
participants found that the most consistent white matter differ-
ences between those with and without ADHD were located in the 
splenium of the corpus callosum extending to the right cingulum, 
the right sagittal stratum, and left tapetum, suggesting problems 
with the connections between the two hemispheres in posterior 
parieto-temporal attention regions and in long-range fronto- 
posterior association tracts (connecting inferior frontal, tempo-
ral, parietal and occipital regions) involved in attention and 
perception (Chen et al., 2016). 
74 A meta-analysis of 21 functional MRI studies with 607 partici-
pants found that those with ADHD showed consistent and repli-
cable under-activation in typical regions of inhibitory control 
such as right inferior frontal cortex, supplementary motor area 
and the basal ganglia relative to typically developing individuals 
(Hart et al., 2013). The inferior frontal under-activation findings 
were replicated in two further fMRI meta-analyses of inhibitory 
control with 33 datasets/1161 participants, and 42 data-
sets/2005 participants, respectively (Lukito et al., 2020; Norman 
et al., 2016). Another meta-analysis including 130 fMRI studies 
with 1914 participants found no convergence except for aberrant 
function in basal ganglia for neutral fMRI tasks and inferior 
frontal under-function in males only (Samea et al., 2019). 
75 A meta-analysis of nine studies with over 1250 research partici-
pants found that elevations in the theta/beta on the electroen-
cephalogram cannot be considered a reliable diagnostic measure 
for ADHD although it may have prognostic value in some patients 
(Arns et al., 2013).  
76 A meta-analysis of six studies with 148 participants examined 
mismatch negativity, which assesses the integrity of auditory 
sensory memory and involuntary attention switching. It reported 
that ADHD children had small-to-moderate reductions in 
mismatch negativity amplitude compared with healthy controls 
(Cheng et al., 2016). 
77 Meta-analyses and systematic reviews showed that the medica-
tions used to treat ADHD are not associated with observed deficits 
in brain structure (Hoogman et al., 2017, 2019; Lukito et al., 
2020; Norman et al., 2016; Spencer et al., 2013), but with 
improved brain function, most prominently in inferior frontal and 
S.V. Faraone et al.                                                                                                                                                                                                                              
Neuroscience and Biobehavioral Reviews 128 (2021) 789–818
798
striatal regions (Hart et al., 2013; Lukito et al., 2020; Norman 
et al., 2016; Rubia et al., 2014; Spencer et al., 2013). 
9. What kinds of non-psychiatric medical problems commonly 
occur among people with ADHD? 
A relatively new area of research into ADHD is examining what types 
of medical problems are more common than expected among people 
with ADHD. As you read this section, keep in mind that not all people 
with ADHD will suffer from all, or even only one, of these disorders. 
9.1. Obesity  
78 A Swedish national register study of over 2.5 million people 
found ADHD patients had a threefold greater risk of obesity 
relative to their non-ADHD siblings and cousins. It also found a 
familial co-aggregation of ADHD and clinical obesity, the 
strength of which varied directly with the degree of genetic 
relatedness (Chen et al., 2018c).  
79 A meta-analysis found that compared with typically developing 
people, children and adolescents with unmedicated ADHD were 
about 20 % more likely to be overweight or obese (15 studies, 
over 400,000 participants), and adults with unmedicated ADHD 
almost 50 % more likely to be overweight or obese (9 studies, 
over 45,000 participants) (Nigg et al., 2016). Meta-analyses of 
twelve studies with over 180,000 participants found that people 
with unmedicated ADHD were about 40 % more likely to be 
obese, whereas those who were medicated were indistinguishable 
from typically developing people (Cortese et al., 2016b). 
9.2. Allergies and asthma  
80 A Swedish national register study of over 1.5 million people 
found that those with asthma were 45 % more likely to have 
ADHD even after adjustment for relevant variables (Cortese et al., 
2018b). A cohort study of almost a million births using the Danish 
national registers found that children born to asthmatic mothers 
were 40 % more likely to develop ADHD (Liu et al., 2019b).  
81 In a meta-analysis of six longitudinal studies with over 50,000 
participants, those with asthma or atopic eczema were a third 
more likely to have ADHD than controls. A meta-analysis of three 
studies with over 48,000 participants found that those with 
allergic rhinitis were about 50 % more likely to have ADHD (van 
der Schans et al., 2017). 
9.3. Diabetes Mellitus  
82 A retrospective analysis of over 650,000 children and adolescents 
in German diagnosis and prescription databases found ADHD was 
40 % more likely to be diagnosed among children with type 1 
diabetes (T1DM) (Kapellen et al., 2016).  
83 A German multi-center registry study of over 56,000 children and 
adolescents found that those with both ADHD and T1DM suffered 
twice as often from diabetic ketoacidosis compared with diabetic 
patients without ADHD. They also found significant differences in 
HbA1c, and concluded, “Pediatric patients with ADHD and T1DM 
showed poor metabolic control compared with T1DM patients 
without ADHD” (Hilgard et al., 2017).  
84 A longitudinal study using the Taiwan National Health Insurance 
Research Database enrolled over 35,000 patients with ADHD and 
over 70,000 age- and sex-matched controls. Adolescents and 
young adults with ADHD were about three times more likely to 
develop type 2 diabetes mellitus (Chen et al., 2018b).  
85 A cohort study using multiple Swedish national registers looked 
at over 1.6 million adults aged 50–64 years. Prevalence of type 2 
diabetes mellitus was 70 % greater among adults with ADHD 
(Chen et al., 2018c).  
86 A meta-analysis found that maternal pre-existing type 1 diabetes 
was associated with a small increased risk of ADHD in offspring (4 
studies, over five million people). So was paternal pre-existing 
type 1 diabetes (3 studies, 4.7 million people), and maternal 
pre-existing type 2 diabetes (2 studies, 2.6 million people) (Zeng 
et al., 2020). A Swedish study looked at all 15,615 children born 
after their parents were diagnosed with type 1 diabetes. After 
controlling for confounders, it found that these children had a 30 
% greater chance of being diagnosed with ADHD (Ji et al., 2018). 
9.4. Other somatic disorders  
87 A meta-analysis of 18 studies with more than 2500 children and 
adolescents found a moderate association between sleep- 
disordered breathing and ADHD (Sedky et al., 2014).  
88 A meta-analysis of sleep in adults with ADHD found no significant 
differences with normally developing adults, as measured by 
polysomnography. In four studies with 178 participants, sleep 
onset latency, stage 1 sleep, stage 2 sleep, slow wave sleep, REM, 
and sleep efficiency were all comparable. Same with total sleep 
time (3 studies, 130 persons), and with REM latency and wake 
after sleep onset (3 studies, 121 persons). As measured by actig-
raphy, there were no significant differences for time in bed and 
actual wake time (3 studies, 159 persons) and true sleep (4 
studies, 222 persons). However, sleep onset latency was much 
greater for those with ADHD, and sleep efficiency was moderately 
lower (4 studies, 222 persons). Nevertheless, subjective evalua-
tions by those with ADHD reported moderately greater difficulty 
in falling asleep (8 studies, over 1700 persons), moderately 
greater frequency of night awakenings and moderately lesser 
likelihood of being rested at wake-up (5 studies, over 1100 per-
sons), and moderately worse sleep quality (5 studies, over 800 
persons)(Lugo et al., 2020).  
89 In a Norwegian national registry study of over 1.2 million males 
and over 1.2 million females, males with ADHD were 30 % more 
likely to be diagnosed with psoriasis, and women with ADHD 
more than 50 % more likely to be diagnosed with psoriasis, than 
normally developing controls (Hegvik et al., 2018).  
90 A Taiwan nationwide population cohort study of over 8000 
people with ADHD and 32,000 matched controls explored asso-
ciations with autoimmune diseases. It reported that those with 
ADHD had well over twice the prevalence of ankylosing spon-
dylitis, ulcerative colitis, and autoimmune thyroid disease, and 
over 50 % greater likelihood of asthma, allergic rhinitis, and 
atopic dermatitis (Chen et al., 2017a).  
91 A population-based cohort study of over 900,000 Danish children 
found that epilepsy was associated with a 2.7-fold increased risk 
for ADHD (Bertelsen et al., 2016). Another population-based 
cohort study, of over 12,000 Taiwanese, reported that epilepsy 
was associated with a 2.5-fold increased risk for ADHD. 
Conversely, a linked cohort study of over 18,000 Taiwanese 
found ADHD was associated with a fourfold increase in epilepsy 
(Chou et al., 2013).  
92 A countrywide registry study of 1.9 million Swedes reported that 
those with epilepsy were three and a half times more likely to 
have ADHD. The risk of having ADHD was 85 % greater if the 
person’s mother had epilepsy, 50–60 % greater if the father or a 
brother or sister did, 15 % greater for cousins. Genetics explained 
40 % of the variance, with non-shared environmental factors 
explaining another 50 % (Brikell et al., 2018).  
93 A longitudinal study using the Taiwan Health Insurance Research 
Database compared almost 18,000 adolescents and young adults 
with ADHD with over 70,000 age- and sex-matched controls. 
Those with ADHD were over three times more likely to develop 
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sexually transmitted infections, after adjusting for demographic 
data, other psychiatric disorders, and ADHD medications (Chen 
et al., 2018a).  
94 A Danish national register cohort study of 1.1 million people 
found that hospitalization for serious infections was associated 
with a subsequent doubling in the rate of ADHD diagnosis. 
Among those treated with anti-infective agents, the risk of sub-
sequent diagnosis with ADHD was halved (Kohler-Forsberg et al., 
2019).  
95 A Danish national register study of almost a million people found 
that children with autoimmune disease were 24 % more likely to 
develop ADHD. Maternal autoimmune disease was associated 
with a 12 % greater likelihood of ADHD in their offspring. 
Paternal autoimmune disease was not associated with any sig-
nificant effect (Nielsen et al., 2017).  
96 Using Taiwan’s nationwide population-based dataset, over 
116,000 children with ADHD were compared with the same 
number of randomly selected children without ADHD. Those with 
ADHD were much more likely to have significant abnormalities of 
the eye: almost 90 % more likely to have amblyopia (“lazy eye”), 
over 80 % more likely to have astigmatism, and twice as likely to 
have heterotropia, in which the eyes diverge at rest (Ho et al., 
2020). A study using the same database matched 6817 youths 
diagnosed with amblyopia to over 27,000 age- and sex-matched 
controls. Those in the amblyopia group had 1.8 times the risk 
of developing ADHD (Su et al., 2019).  
97 In a study of over 2.5 million German youth, those with ADHD 
were nine times more likely to have metabolic disorders, five 
times more likely to develop viral pneumonia, four times more 
likely to have white blood cell disorders, three times more likely 
to have kidney failure, high blood pressure, or be obese, two and 
a half times more likely to have type 2 diabetes or migraines, 
twice as likely to have asthma or atopic dermatitis, and 50 % 
more likely to have glaucoma (Akmatov et al., 2019). A Brazilian 
population-based study including 5671 children found those with 
migraine about four times more likely to have ADHD (Arruda 
et al., 2020).  
98 A study of over 59,000 boys diagnosed with ADHD and over 
52,000 healthy boys in Taiwan reported that those in the ADHD 
group were twice as likely to develop testicular dysfunction 
(Wang et al., 2019).  
99 A nationwide population cohort study using the Swedish national 
registers compared over 19,000 children with a diagnosis of 
biopsy-verified celiac disease with over 95,000 matched child 
controls. It found a subsequent 29 % increased risk of ADHD in 
the celiac patients, rising to 39 % when restricting to adult di-
agnoses of ADHD. However, when comparing 13,000 children 
diagnosed with celiac disease to their 18,000 non-celiac siblings, 
the increases became nonsignificant, suggesting the increases 
were primarily attributable to confounders (Lebwohl et al., 
2020).  
100 A Swedish nationwide study using national registers examined 
medical records of all individuals aged 18–64 years who were 
residing in Sweden during 2013 and identified 41,840 who filled 
at least one prescription for ADHD medicines. Young adults with 
ADHD were four times more likely to have somatic co- 
prescriptions and fifteen times more likely to have psychotropic 
co-prescriptions than normally developing controls. For middle- 
aged adults (30–49) the odds were six and 21 times greater, 
respectively, and for older adults, seven and 18 times greater. 
Respiratory medications (primarily for allergic reactions and 
asthma) were the most likely to be dispensed for somatic pur-
poses, followed by alimentary tract and metabolic medications 
(most frequently proton pump inhibitors indicated for gastric/ 
duodenal ulcers and gastroesophageal reflux disease), then 
cardiovascular system medications (primarily for hypertension 
and arrhythmias) (Zhang et al., 2020a). 
10. What is the impact of ADHD on patients and families? 
ADHD is a disorder associated with serious distress and/or impair-
ments in living. Although, as documented below, many severe adverse 
outcomes have been associated with ADHD, the typical patient does not 
experience all, or even most, of these problems. Many patients live 
enjoyable and productive lives, especially if they receive treatment. 
10.1. Quality of life  
101 A meta-analysis of seven studies with over 5000 youths and their 
parents reported large impairments in the quality of life of youths 
with ADHD relative to typically developing peers, regardless of 
whether evaluated by the youths themselves or by their parents. 
Physical functioning was only moderately impaired, but 
emotional functioning and social functioning was strongly 
impaired. School functioning was strongly impaired. As youths 
with ADHD grew older, their quality of life compared with typi-
cally developing peers grew worse in physical, emotional, and 
school domains (Lee et al., 2016).  
102 A meta-analysis of 17 studies encompassing 647 families (over 
2300 participants) evaluated the quality of life of parents whose 
children had ADHD relative to parents with typically developing 
children. Parents of the former reported a moderate deficit in 
quality of life relative to parents of the latter (Dey et al., 2019). 
10.2. Emotional and social impairment  
103 A study of over 8600 youths from the U.S. National Health 
Interview Survey found that those with ADHD were six times as 
likely to have a high level of emotional, conduct, and peer 
problems, and nine times as likely to manifest a high level of 
impairment including interference with home life, friendships, 
classroom learning, and leisure activities (Strine et al., 2006).  
104 A meta-analysis of 22 studies with over 21,000 participants found 
that youths with ADHD were strongly impaired in the ability to 
modulate their reactivity to novel or stressful events (Graziano 
and Garcia, 2016). Another meta-analysis, combining twelve 
studies with over 1900 participants, found that adults with ADHD 
had very elevated levels of emotional dysregulation compared 
with normally developing controls (Beheshti et al., 2020).  
105 A meta-analysis found that children with ADHD had medium-to- 
large impairments in socializing with peers as measured by 
rejection/likability, popularity, and friendships (61 studies, over 
24,000 children). They also had moderate impairments in social 
skills such as sharing, cooperating, turn-taking, reciprocity (68 
studies, over 148,000 children), and social-information process-
ing, such as recognizing social cues, identifying problems, 
generating solutions, and avoiding biases (23 studies, over 3750 
children) (Ros and Graziano, 2018).  
106 A study of over 53,000 U.S. children from the National Survey of 
Children’s Health found that those with ADHD were 2.4 times as 
likely to engage in bullying (Montes and Halterman, 2007). A 
more recent study of some 64,000 children using the same 
database confirmed this finding, reporting that those with ADHD 
were 2.8 times more likely to engage in bullying (Benedict et al., 
2015). 
10.3. Accidental injuries  
107 A nationwide cohort study of over 50,000 youths with ADHD and 
an equal number of age-, sex-, and comorbidity-matched controls 
drawn from Taiwan’s National Health Insurance Research 
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Database reported that having ADHD was associated with a more 
than three-quarters greater likelihood of burn injury. For those 
under six years old, the risk was doubled. For youths between six 
and seventeen years old, the increase in risk was about 70 
percent. There were no significant differences between boys and 
girls (Yeh et al., 2020).  
108 A meta-analysis of 32 studies covering more than four million 
people found that those with ADHD had a 40–50 % greater risk of 
accidental physical injuries (Ruiz-Goikoetxea et al., 2018a).  
109 A Swedish national registers study followed 17,408 individuals 
with ADHD from 2006 to 2009 and found that patients with 
ADHD had an almost 50 % greater risk of serious transport ac-
cidents (Chang et al., 2014b).  
110 A U.S. study of over 8000 high school and collegiate athletes 
(predominantly male football players) found that those with 
ADHD were three times as likely to have had three or more re-
ported concussions (Nelson et al., 2016).  
111 A meta-analysis of 16 studies encompassing over 175,000 people 
estimated that controlling for mileage driven, those with ADHD 
were 23 % more likely to be involved in vehicular crashes (Vaa, 
2014).  
112 A retrospective cohort study of over 18,000 New Jersey drivers 
found that the crash risk for those with ADHD was a third greater 
than for those without (Curry et al., 2017).  
113 A meta-analysis of five studies, comprising over three thousand 
patients with minor traumatic brain injury (mTBI) and over nine 
thousand controls found that those with mTBI were twice as 
likely to have ADHD than those without mTBI (Adeyemo et al., 
2014). 
10.4. Premature death and suicide  
114 A Danish study of almost two million people found ADHD is 
associated with a small risk for premature death, mostly due to 
accidents. When ADHD was accompanied by other psychiatric 
and substance use disorder, the chances of premature death 
increased (Dalsgaard et al., 2015b).  
115 A cohort study of more than 2.2 million Taiwanese found no 
increased risk of death from natural-causes associated with 
ADHD. But people with ADHD had twice the rate of suicide, twice 
the rate of death by homicide, and a 30 % greater rate of death 
from unintentional injury (Chen et al., 2019c).  
116 Using nationwide registers in Denmark, a cohort study of 2.9 
million people reported a fourfold higher rate of suicide attempts 
and deaths in patients with ADHD. The risk was over tenfold in 
those with ADHD plus another psychiatric diagnosis (Fitzgerald 
et al., 2019).  
117 A meta-analysis found that persons with ADHD attempted suicide 
at twice the rate of typically developing people (six studies, over 
65,000 persons), had over three times the rate of suicidal ideation 
(23 studies, over 70,000 persons), and over six times the rate of 
completed suicide (four studies, over 130,000 persons) (Septier 
et al., 2019).  
118 A Taiwanese study of over 20,000 adolescents and young adults 
with ADHD and over 61,000 age- and sex-matched non-ADHD 
individuals found that those with ADHD were almost four times 
as likely to attempt suicide, and over six times as likely to repeat 
suicide attempts. Methylphenidate or atomoxetine treatment did 
not increase the risk of suicide attempts or repeated suicide at-
tempts. Long-term methylphenidate treatment was associated 
with a lower risk for repeated suicide attempts among men 
(Huang et al., 2018b).  
119 In a prospective cohort study of more than 2.6 million Swedes, 
adults with ADHD had a small increase in premature death, 
mostly due to accidents and suicide. There was no significant 
association for children with ADHD (Sun et al., 2019b). 
10.5. Crime and delinquency  
120 A study of the Danish population using nationwide registers 
found that, compared with other youth, those diagnosed with 
ADHD were more than twice as likely to be convicted of criminal 
offenses and were three times as likely to be incarcerated. After 
adjusting for other risk factors, those with ADHD were 60 % more 
likely to have been convicted of a crime, and 70 % more likely to 
have been incarcerated (Mohr-Jensen et al., 2019).  
121 A meta-analysis comprising 21 studies and over 19,500 prison 
inmates found that the prevalence of ADHD in prisons based on 
interview diagnoses was 20.5 % with no differences observed 
between males and females or adolescents and adults (Young 
et al., 2015). Another meta-analysis reported the prevalence of 
ADHD among adolescents in juvenile detention to be just over 17 
%, both for males (24 studies, over 24,000 individuals) and fe-
males (13 studies, over 3900 individuals), which is much higher 
than the prevalence in the population (Beaudry et al., 2021).  
122 A study using a nationally representative American sample of 
over 5000 adults found that those with ADHD were over twice as 
likely to be perpetrators of physical dating violence, and 65 % 
more likely to be victims of such violence (McCauley et al., 2015).  
123 In a nationwide study of over 21,000 Icelandic adolescents and 
young adults, 14 % reported having been interrogated at a police 
station. Of these, 15 % reported making a false confession. Those 
with ADHD were twice as likely to make a false confession 
(Gudjonsson et al., 2016).  
124 A study using the Danish national registries looked at violent 
crimes against youths aged 7–18 years, among a total of 678,000 
individuals. Children with ADHD were 2.7 times more likely to be 
victims of violent crimes than their typically developing peers, 
after adjusting for confounding risk factors (Christoffersen, 
2019). 
10.6. Educational underachievement  
125 A study of a U.S. sample of almost 30,000 adults found that those 
with ADHD were twice as likely not to have graduated from high 
school on time, after adjusting for other psychiatric disorders 
(Breslau et al., 2011). 
126 A nationwide cohort study of over 750,000 Scottish school chil-
dren using linked national registers identified those who had 
been prescribed medicine for ADHD. Even while receiving 
medication, these children were more than three times as likely 
as typically developing peers to have low educational achieve-
ment, more than twice as likely to drop out of school before age 
16, more than eight times as likely to have a record of special 
educational needs, 50 % more likely to get injured, and 40 % 
more likely to be unemployed. These results were adjusted for 
socioeconomic confounders and other psychiatric conditions 
(Fleming et al., 2017).  
127 A meta-analysis of ten studies and 830 youths found that ADHD 
was strongly associated with poorer performance on measures of 
overall, expressive, receptive, and pragmatic language (Korrel 
et al., 2017). 
10.7. Substance use disorders  
128 A meta-analysis of twelve studies covering over 5400 people 
found that those with ADHD were almost three times more likely 
to be nicotine-dependent. Combining eleven studies with almost 
2400 participants, those with ADHD were 50 % more likely to 
develop a drug or alcohol use disorder than those without ADHD 
(Lee et al., 2011).  
129 A meta-analysis found that ADHD was associated with a more 
than twofold greater odds of alcohol-use disorders (13 studies, 
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over 20,000 participants) and nicotine-related disorder (14 
studies, over 1800 participants) (Groenman et al., 2017).  
130 A Swedish study of over half a million people found a more than 
threefold association between ADHD and subsequent drug use 
disorders after adjusting for sex and parental education (Sund-
quist et al., 2015). 
10.8. Other  
131 Studies of 2.7 million girls from Denmark (Ostergaard et al., 
2017), 380,000 from Sweden (Skoglund et al., 2019) and 7500 
from Taiwan (Hua et al., 2020) found that those with ADHD were 
more likely to have teen pregnancies than those without ADHD. 
Consistent with these results, large studies from Sweden (Chang 
et al., 2014a), Finland (Chudal et al., 2015) and a consortium of 
eight European countries (Pohlabeln et al., 2017) each found 
ADHD to be more likely among children of teenage mothers than 
among children of older mothers.  
132 A study of over 36,000 people from the U.S. reported that ADHD 
increased the risks for problem gambling, spending too much 
money, reckless driving, and quitting a job without a plan for 
what to do next (Bernardi et al., 2012).  
133 A nationwide study using Taiwan’s National Health Insurance 
Research Database compared 675 adults with ADHD and 2025 
without ADHD, matched by age and sex. After adjusting for other 
psychiatric disorders, urbanization level of residence, and 
monthly income, those with ADHD had 3.4 times the risk of 
developing dementia (Tzeng et al., 2019).  
134 A meta-analysis of nine studies encompassing almost a million 
and a half people found that ADHD is associated with a threefold 
greater risk of poisoning in children (Ruiz-Goikoetxea et al., 
2018b). In a study from Taiwan comparing 3685 children with 
ADHD with 36,000 controls, those with ADHD had a more than 
fourfold greater risk of deliberate self-poisoning (Chou et al., 
2014).  
135 A longitudinal study of some 15,000 U.S. adolescents reported 
that those with ADHD had a 12 % reduction in employment and a 
34 % reduction in earnings relative to non-ADHD siblings 
(Fletcher, 2014).  
136 Using Danish registers, a nationwide population study of over 
675,000 youths between the ages of 7 and 18 found that youths 
with ADHD were 3.7 times as likely to be reported as victims of 
sexual crimes than normally developing controls. After adjusting 
for covariates, such as parental violence, parental inpatient 
mental illness, parental suicidal behavior or alcohol abuse, 
parental long-term unemployment, family separation, and child 
in public care outside the family, youths with ADHD remained 
almost twice as likely to be reported as victims of sexual crimes 
(Christoffersen, 2020). 
11. What is the economic burden of ADHD? 
Given the many adverse outcomes associated with ADHD, it will 
come as no surprise to readers that these effects have a substantial 
economic cost to individual patients, families, and society.  
137 A systematic review of seven European studies of hundreds of 
thousands of participants estimated total ADHD-related costs in 
the Netherlands as €9860 to €14,483 per patient per year, with 
annual national costs more than €1 billion (Le et al., 2014).  
138 A review of the costs of child, youth and adult ADHD in Australia 
estimated the total annual costs to be over $20 billion Australian 
dollars, or $25,000 per person with ADHD. This includes finan-
cial costs of $12.8 billion, well-being losses of $7.6 billion, and 
productivity losses of $10.2 billion (Australian ADHD Pro-
fessionals Association, 2019).  
139 A systematic review of 19 U.S. studies of hundreds of thousands 
of people found that ADHD was associated with overall national 
annual costs from $143 to $266 billion, mostly associated with 
adults ($105 to $194 billion). Costs borne by family members of 
people with ADHD ranged from $33 - $43 billion (Doshi et al., 
2012).  
140 A study with over 7000 workers in ten nations found that those 
with ADHD had an average of 22 annual days of lost role per-
formance compared with those without ADHD (de Graaf et al., 
2008).  
141 A study of a U.S. national Fortune 100 company’s database of 
over 100,000 beneficiaries compared healthcare costs for youths 
with ADHD with matched controls without ADHD. The annual 
average cost per family member was $2728 for non-ADHD family 
members of ADHD patients, almost double the $1440 for family 
members of matched controls (Swensen et al., 2003).  
142 German health insurance records, including over 25,000 patients 
with ADHD, indicate that patients with ADHD cost roughly €1500 
more annually than those without ADHD. Main cost drivers were 
inpatient care, psychiatrists, and psychotherapists. Mood, anxi-
ety, substance use disorders, and obesity were significantly more 
frequent in patients with ADHD. The additional costs resulting 
from these conditions added as much as €2800 per patient 
(Libutzki et al., 2019).  
143 Using the National Health Insurance Service claims data for the 
population aged 19 years or younger in South Korea (69,353 
diagnosed with ADHD), the total annual economic burden due to 
ADHD was estimated to be $47.55 million (Hong et al., 2020).  
144 Using the Danish national registers, over 5000 adults with a 
diagnosis of ADHD in adulthood who had not received a diag-
nosis in childhood were identified. Excluding cases with missing 
data, other psychiatric diagnoses, and cases without a same-sex 
sibling free of any diagnosed psychiatric diagnoses, a final 
cohort was formed consisting of 460 sibling pairs. On average, 
adults with ADHD had an annual economic burden of just over 
€20,000 compared with their normally developing siblings 
(Daley et al., 2019).  
145 A nationwide cohort study of over 445,000 people in the Swedish 
national registers compared healthcare costs for three groups: 
those with childhood ADHD that persisted into adulthood, those 
whose ADHD remitted in adulthood, and those who never had 
ADHD. Those who never had ADHD had average annual health-
care costs of €304. Those in remission had double the cost, and 
those with persistent ADHD over triple the cost (Du Rietz et al., 
2020).  
146 A nationwide population study of over 83,000 persons with 
ADHD and over a third of a million non-ADHD controls matched 
by age and sex used Danish national registries to calculate the net 
socioeconomic cost of ADHD. Relative to controls, and summing 
net direct health costs and net losses from lower income and 
employment, the yearly average cost per individual with ADHD 
came to just over €16,000. Including additional social transfers, 
the total rose to just over €23,000. For partners of persons with 
ADHD, the additional yearly average cost per individual was 
almost €5500. With additional social transfers, the total rose to 
€8000 (Jennum et al., 2020).  
147 Using a database that tracks more than sixty German nationwide 
health insurance programs, a study of five million member re-
cords identified 2380 individuals first diagnosed with ADHD as 
adults. Their direct healthcare costs in the year following diag-
nosis averaged €4000. Despite explicit German guidelines rec-
ommending ADHD medication, only a third were prescribed 
medication, dropping to one eighth four years later. Two-thirds 
received psychotherapy. The authors concluded that "guideline 
recommendations are not yet comprehensively implemented in 
everyday routine care” (Libutzki et al., 2020). 
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12. Which medications are safe and effective for treating ADHD? 
As determined by governmental regulatory agencies around the 
world, several medications are safe and effective for treating ADHD 
symptoms as determined by randomized controlled clinical trials that 
typically study patients for several weeks. These medications, which are 
as efficacious, or more efficacious, than many medications used for non- 
psychiatric disorders (Leucht et al., 2012), are classified as either stim-
ulants (methylphenidate and amphetamine) or non-stimulants (atom-
oxetine, extended release guanfacine, and extended release clonidine). 
12.1. Effects of medications on symptoms: results from randomized, 
controlled clinical trials  
148 Protocols for using medications for ADHD are well described in 
detailed guidelines prepared by professional health care associ-
ations (Alliance, 2011; Banaschewski et al., 2018; Bolea-Alama-
nac et al., 2014; Crunelle et al., 2018; Flisher and Hawkridge, 
2013; Graham et al., 2011; Kooij et al., 2019; National Collabo-
rating Centre for Mental Health, 2018; National Institute for 
Health Care and Excellence, 2018a,b; Pliszka, 2007; Schoeman 
and Liebenberg, 2017; Seixas et al., 2012; Taylor et al., 2004; 
Wolraich et al., 2011).  
149 A network meta-analysis found stimulants to be highly effective 
in reducing the symptoms of ADHD. Compared with placebo, as 
rated by clinicians, amphetamines were associated with large 
improvements in all age groups (youths 6 studies with 2179 
participants, adults 5 studies with 1521 participants), methyl-
phenidate with large improvements in youths (9 studies, 2677 
participants) and moderate ones in adults (11 studies, 2909 
participants). Extended release guanfacine (7 studies, 1930 par-
ticipants) led to moderate improvements in children. Atom-
oxetine led to moderate improvements in all age groups (youths 
21 studies with 3812 participants, adults 11 studies with 3377 
participants). Taking side effects into account, the medications 
with the best benefit-to-risk ratios were methylphenidate for 
children and adolescents, and amphetamines for adults (Cortese 
et al., 2018a).  
150 A meta-analysis of 18 studies with over 2000 adults with ADHD 
found three amphetamine derivatives (dextroamphetamine, lis-
dexamfetamine, and mixed amphetamine salts) to be associated 
with moderate reductions in ADHD symptoms (Castells et al., 
2011). Another meta-analysis, combining four studies with 216 
youths, found mixed amphetamine salts to be slightly more 
effective at reducing ADHD symptoms than methylphenidate 
(Faraone et al., 2002). 
151 A meta-analysis of 19 parallel group trials with over 1600 par-
ticipants found methylphenidate produced moderate to large 
improvements in teacher-rated ADHD symptoms, teacher-rated 
behavior, and parent-rated quality of life. There was no evi-
dence of serious adverse events, and just a slightly elevated risk of 
non-serious side effects (Storebø et al., 2015).  
152 A meta-analysis found dexmethylphenidate strongly reduced 
youth ADHD symptoms relative to placebo (seven studies, almost 
1500 participants), and had three times the clinical response rate 
(four studies, over 600 participants) (Maneeton et al., 2015). 
Another meta-analysis, covering six RCTs with 253 participants, 
reported that methylphenidate strongly reduced adult ADHD 
symptoms, with higher doses resulting in greater improvement 
(Faraone et al., 2004). 
153 A meta-analysis of seven studies with over 1600 participants re-
ported that atomoxetine moderately reduced ADHD symptoms. 
(Cheng et al., 2007).  
154 A meta-analysis found that methylphenidate (13 studies, over 
2200 adults) and lisdexamfetamine (five studies, over 2300 
adults) led to small-to-moderate reductions in symptoms of 
emotional dysregulation; for atomoxetine (three studies, 237 
adults) the reductions were small (Lenzi et al., 2018). Another 
meta-analysis covering nine studies with over 1300 youths re-
ported atomoxetine to be associated with small reductions in 
emotional symptoms (Schwartz and Correll, 2014).  
155 A meta-analysis reported moderate-to-strong improvements in 
ADHD symptoms with methylphenidate in ADHD patients with 
borderline intellectual functioning or intellectual disability (8 
studies, 423 children). (Sun et al., 2019a).  
156 A meta-analysis of 23 studies with over 2900 children with ADHD 
reported that stimulant medications reduced anxiety by 14 % 
relative to placebo (Coughlin et al., 2015).  
157 A meta-analysis of nine studies with over 1300 participants found 
stimulants to be highly effective in reducing aggression, opposi-
tional behavior, and conduct problems in youths with ADHD 
(with and without oppositional defiant disorder) and conduct 
disorder, as measured by teachers, and moderately effective as 
measured by parents (Pringsheim et al., 2015). 
12.2. Effects of medications on impairments associated with ADHD: 
results from naturalistic studies  
158 A Swedish registry study of over 650,000 students found that 
treatment with ADHD medication for three months resulted in a 
more than nine-point gain in grade point sum (on a scale of 
0–320); treatment was associated with an increase in the proba-
bility of completing upper secondary school by two-thirds 
(Jangmo et al., 2019).  
159 A Swedish national register study of over 61,000 youths with 
ADHD found that their test scores were higher during periods 
they were taking medication vs non-medicated periods (Lu et al., 
2017). A Danish study of over half a million children (over 6400 
with ADHD) found that discontinuation of ADHD medication was 
associated with a small but significant decline in grade point 
averages (Keilow et al., 2018). A meta-analysis of nine RCTs 
comprising 1463 patients found that discontinuing medications 
led to a worsening in quality of life for children and adolescents 
but not adults. (Tsujii et al., 2020)  
160 A Swedish cohort study of over 25,000 ADHD patients found a 
one-third reduction in criminality among men receiving ADHD 
medication, and a 40 % reduction for women (Lichtenstein et al., 
2012). A Danish national registry study of over 4200 individuals 
with childhood ADHD found that crime rates in adulthood were 
30–40 % lower during periods of taking ADHD medication 
(Mohr-Jensen et al., 2019).  
161 A Danish cohort study of over 700,000 people, including 4557 
with ADHD, found that among teenagers with ADHD, stimulant 
treatment was associated with a decrease in rates of injuries (30 
% for ten-year olds and 40 % for twelve-year olds) (Dalsgaard 
et al., 2015a).  
162 Using the Swedish national registries, a study followed 9421 
youths with ADHD and 2986 youths with both ADHD and other 
psychiatric diagnoses from 2006 to 2013. It compared periods 
when they were taking ADHD medication with periods when they 
were not. During medicated periods both groups had a greater 
than 10 % reduction in unintended injuries, and a greater than 70 
% reduction in traumatic brain injuries (Ghirardi et al., 2020).  
163 A Taiwanese study of over 124,000 youths with ADHD found that 
methylphenidate treatment above an annual average cumulative 
defined daily dose of 84 halved the risk for traumatic brain in-
juries, after adjusting for confounders (Liao et al., 2018).  
164 A nationwide study compared 7200 Taiwanese youths with 
ADHD with 36,000 children without ADHD. After adjusting by 
age, sex, urbanization level, and geographic region, boys with 
ADHD were almost 40 % more likely and girls with ADHD 60 % 
more likely to suffer bone fractures (Guo et al., 2016). Another 
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study from Taiwan identified over 6200 youths newly diagnosed 
with ADHD and assessed the effect of methylphenidate treatment. 
The risk of bone fractures was 20 % lower in those who had over 
half a year of methylphenidate treatment (Chen et al., 2017b).  
165 A population-based, electronic medical records database in Hong 
Kong identified over 17,000 individuals aged 6–19 years who had 
been prescribed methylphenidate. Of these, almost 5000 had at 
least one trauma-related emergency room admission. Researchers 
found a 9 % reduction in such admissions during periods covered 
by a methylphenidate prescription compared with periods with 
no active prescription (Man et al., 2015).  
166 A meta-analysis of five studies with over 13,000 participants 
found that ADHD medications (primarily stimulants) were asso-
ciated with a greater than 10 % reduction in unintentional in-
juries (Ruiz-Goikoetxea et al., 2018a).  
167 Using Swedish national registers, a study of over 17,000 people 
with ADHD found that medication for ADHD was associated with 
a greater than 50 % reduction in the risk of serious transport 
accidents among males but not females. Over 40 % of crashes by 
male patients would have been avoided if they had been receiving 
treatment during the entire period (Chang et al., 2014b). A U.S. 
national cohort study of 2.3 million people with ADHD examined 
emergency room visits for motor vehicle crashes over ten years. 
Males with ADHD had a 38 % lower risk of crashes in months 
when receiving ADHD medication compared with months when 
not receiving medication, and females a 42 % lower risk in 
months when receiving ADHD medication. About a fifth of 
crashes would have been avoided if they had been on medication 
throughout the period of the study (Chang et al., 2017).  
168 A longitudinal study using the Taiwan Health Insurance Research 
Database compared almost 18,000 adolescent and young adults 
with ADHD with over 70,000 age- and sex-matched controls. 
Short-term use of ADHD medications was associated with a 30 % 
reduction in sexually transmitted infections, and long-term use 
with a 40 % reduction, though these reductions were only among 
males (Chen et al., 2018a). 
169 A nationwide longitudinal cohort study using the Swedish na-
tional registers found that among more than 38,000 individuals 
with ADHD, ADHD medication was associated with a greater than 
40 % reduction in the risk for depression three years later. The 
risk decreased with the duration of ADHD medication use. 
Depression was 20 % less common when patients received ADHD 
medication compared with periods when they did not (Chang 
et al., 2016).  
170 A Swedish population-based study of 38,000 people with ADHD 
found a 20 % decline in suicide related events among those pre-
scribed stimulants during periods when they were under treat-
ment as opposed to during periods when they were not under 
treatment. No such benefit was found for non-stimulant medi-
cations (Chen et al., 2014).  
171 A Taiwanese study identified 85,000 youths with ADHD using 
National Health Insurance data to examine whether methylphe-
nidate use affected suicide attempts. After adjusting for relevant 
variables, it found a 60 % lower risk of suicide in those using 
methylphenidate for 3 months to half a year, and a 70 % reduc-
tion among those using methylphenidate for more than half a 
year (Liang et al., 2018b).  
172 A study using the Swedish national registers investigated the 
association between prescription stimulant medication for ADHD 
in 2006 and substance abuse during 2009 among all 38,753 
people born between 1960 and 1998 and diagnosed with ADHD. 
After controlling for relevant variables, it found a greater than 30 
% reduction in indicators of substance abuse among those pre-
scribed stimulants. The longer the duration of medication, the 
lower the rate of substance abuse (Chang et al., 2014c). A 
meta-analysis of 14 studies with over 2300 participants found 
that people with ADHD were about half as likely to smoke ciga-
rettes when regularly treated with stimulant medications 
(Schoenfelder et al., 2014). A meta-analysis found that stimulants 
did not increase the risk for alcohol (11 studies, over 1300 par-
ticipants, nicotine (6 studies, 884 participants), cocaine (7 
studies, 950 participants), or cannabis abuse or dependence (9 
studies, over 1100 participants) (Humphreys et al., 2013).  
173 A nationwide study of over 7500 Taiwanese adolescents with 
ADHD and over 30,000 matched controls found that long-term 
use of ADHD medication use was associated with a 30 % 
decrease in teenage pregnancy (Hua et al., 2020).  
174 A nationwide population-based cohort using Taiwan’s National 
Health Insurance Research Database identified over 68,000 
children and adolescents with a diagnosis of ADHD and who were 
prescribed methylphenidate and compared them with an iden-
tical number of controls matched on age, gender, and year of first 
ADHD diagnosis. After controlling for potential confounders, 
ADHD individuals prescribed methylphenidate had a one-fifth 
lower rate of all-cause mortality than ADHD individuals not 
prescribed methylphenidate. Delayed use of methylphenidate, on 
the other hand, was associated with slightly higher (5 %) mor-
tality. Long-term methylphenidate use was associated with a one- 
sixth lower rate of all-cause mortality. The authors caution, 
however, that "information lacking in the database precluded the 
measurement of other possible confounders, such as family his-
tory, psychosocial stressors, effect of behavioural therapy or 
severity of comorbidities,” and thus unmeasured confounding 
cannot be excluded (Chen et al., 2020a).  
175 A nationwide population-based cohort using Taiwan’s National 
Health Insurance Research Database identified over 90,000 in-
dividuals younger than 18 years with a diagnosis of ADHD, and 
compared risk of burn injury between those not on methylphe-
nidate, those on methylphenidate for less than 90 days, and those 
on methylphenidate for more than 90 days. The data suggested 
that fully half the incidence of burn injuries could have been 
prevented by taking methylphenidate. Compared with patients 
not taking methylphenidate, those taking it for less than 90 days 
had a 30 % lesser risk of burn injuries, and those taking it for 90 
days or more a 57 % reduction in risk, after adjusting for con-
founders (Chen et al., 2020b). 
12.3. Effects of medications for ADHD on the brain  
176 A meta-analysis of methylphenidate treatment for ADHD found 
moderate improvements in response inhibition (25 studies, 787 
participants) and sustained attention (29 studies, 956 partici-
pants), but no significant effect on working memory (13 studies, 
559 participants) (Tamminga et al., 2016).  
177 A meta-analysis of 14 fMRI studies with 212 participants reported 
that medication treatment for ADHD made the brains of youths 
with ADHD function in a way that was more like the brains of 
people without ADHD in brain areas involved in the control of 
cognition, which is typically disrupted in ADHD (Rubia et al., 
2014). Medication treatment for ADHD had no effect on brain 
structure in studies of 4180 ADHD patients in the ENIGMA-ADHD 
Working Group set of 36 cohorts from around the world (Hoog-
man et al., 2017, 2019). 
12.4. Adverse effects of ADHD medications  
178 A meta-analysis found that stimulants moderately reduced total 
sleep time (7 studies, 223 children), delayed the onset of sleep (7 
studies, 171 children), and slightly-to-moderately decreased 
sleep efficiency (7 studies, 155 children) (Kidwell et al., 2015). A 
meta-analysis found that children and adolescents on methyl-
phenidate were 50 % more likely to report abdominal pain (46 
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studies, over 4600 youths) and over three times more likely to 
experience decreases in appetite (52 studies, over 4800 youths) 
and weight (7 studies, over 850 youths) (Holmskov et al., 2017). 
An umbrella review of network meta-analyses and meta-analyses 
of RCTs and cohort studies examined 78 adverse events across 19 
categories of 80 psychotropic medications in children and ado-
lescents with mental disorders including data from nine network 
meta-analyses, 39 meta-analyses, 90 individual RCTs, and eight 
cohort studies with a total of 337,686 children and adolescents 
included (Solmi et al., 2020). Five medications for ADHD were 
associated with significantly worse anorexia (atomoxetine, 
D-amphetamine, lisdexamphetamine, methylphenidate, mod-
afinil), four with insomnia (d-amphetamine, lisdexamphetamine, 
methylphenidate, modafinil), three with weight loss (atom-
oxetine, methylphenidate, modafinil), two each with abdominal 
pain (methylphenidate, guanfacine), discontinuation due to 
adverse event (lisdexamphetamine, guanfacine), hypertension 
(atomoxetine, lisdexamphetamine), and sedation (clonidine, 
guanfacine), and one with QT prolongation (guanfacine).  
179 A meta-analysis of twelve studies with over 3300 adults found 
that those taking atomoxetine were about 40 % more likely to 
discontinue treatment due to adverse events than those on pla-
cebo (Cunill et al., 2013). A meta-analysis found that methyl-
phenidate was more than twice as likely to induce insomnia as 
atomoxetine (10 studies, over 3000 youths), but about half as 
likely to cause nausea (8 studies, over 2750 youths) and vomiting 
(97 studies, over 2500 youths), and about a sixth as likely to 
cause drowsiness (9 studies, over 2800 youths) (Liu et al., 2017a). 
A meta-analysis of methylphenidate treatment studies reported a 
55 % increase in adverse events relative to placebo, none 
life-threatening (11 studies, over 2100 youths), but a fivefold 
increase in anorexia (3 studies, 613 youths), and more than 
fourfold increase in insomnia (4 studies, 749 youths) (Ching 
et al., 2019).  
180 Children treated with stimulants may show delays in expected 
height gains averaging two centimeters over one or two years. 
These sometimes attenuate over time and often reverse when 
treatment is stopped (Faraone et al., 2008). A medical records 
study from the USA comparing over 32,000 stimulant-treated 
ADHD children with over 11,000 controls found continuing de-
clines in expected height over a four-year period. A study from 
Germany, however, specifically addressed whether stimulants 
predicted patients being very short (i.e., being less than or equal 
to the third percentile of the population). After comparing 3806 
boys not treated with methylphenidate with 118 treated boys, the 
results did not indicate that methylphenidate increased the 
probability of this adverse outcome (McCarthy et al., 2018).  
181 A study using Danish national registers followed over 700,000 
individuals for an average period of almost a decade. Looking at 
8300 people with ADHD, stimulant users had more than twice the 
rate of cardiovascular events (primarily hypertension) than 
nonusers. These events were rare (Dalsgaard et al., 2014).  
182 A meta-analysis of five studies with over 43,000 children and 
adolescents found no significant difference in adverse cardiac 
events between methylphenidate and atomoxetine, and a meta- 
analysis of three studies with 775 adults found no significant 
difference in adverse cardiac events between methylphenidate 
and placebo (Liang et al., 2018a). 
183 A meta-analysis covering people of all ages reported methyl-
phenidate was not associated with a higher risk of all-cause death 
(3 studies, over 1.4 million people), heart attack or stroke (3 
studies, over half a million people) (Liu et al., 2019a).  
184 A cohort study of over 1.8 million pregnancies in the United 
States and over 2.5 million pregnancies in the health registries of 
Denmark, Finland, Sweden, Norway, and Iceland reported that 
use of methylphenidate (but not amphetamines) by pregnant 
women was associated with a higher risk for cardiac malforma-
tions from 12.9 per thousand infants to 16.5 per thousand infants 
(Huybrechts et al., 2018). A meta-analysis of four studies of three 
million women also found that intrauterine exposure to methyl-
phenidate was associated with a higher risk of cardiac malfor-
mations (Koren et al., 2020).  
185 A meta-analysis examining the safety of atomoxetine found no 
significant increase in risk of irritability (3 studies, over 1100 
children) (Pozzi et al., 2018). Two others, one combining twenty 
studies with over 3000 participants, and another combining 37 
studies with over 3800 participants, found no increase in risk of 
all-cause treatment discontinuation in youths (Catala-Lopez 
et al., 2017; Schwartz and Correll, 2014). However, a 
meta-analysis of twelve studies with over 3300 adults found 40 % 
greater rate of all-cause treatment discontinuation, leading to a 
conclusion that “atomoxetine has a poor benefit–risk balance for 
the treatment of adults with ADHD” (Cunill et al., 2013).  
186 The Hong Kong Clinical Data Analysis & Reporting System, a 
population-based, electronic medical records database, was used 
to examine over 25,000 people receiving methylphenidate for 
ADHD. During the 90-day period prior to initiation of treatment, 
individuals with ADHD were over six times more likely to attempt 
suicide than after treatment. After ongoing treatment, the risk for 
attempted suicide was no longer elevated among patients with 
ADHD (Man et al., 2017).  
187 Using the same Hong Kong database, the risk for psychosis did 
not differ between periods when patients were on and off meth-
ylphenidate treatment (Man et al., 2016).  
188 A Swedish registry study of over 23,000 adolescents and young 
adults treated with methylphenidate for ADHD found no evi-
dence for an association between psychosis and methylphenidate 
treatment. A year after initiation of methylphenidate treatment, 
the incidence of psychotic events was 36 % lower in those with a 
history of psychosis and 18 % lower in those without a history of 
psychosis relative to the period immediately before the beginning 
of treatment (Hollis et al., 2019). 
12.5. Misuse and diversion of stimulant medications  
189 A systematic review of 109 studies concluded that the non- 
medical use of prescribed stimulants is a significant public 
health problem, especially in college students. Most non-medical 
use is associated with zero or minor medical effects, but adverse 
medical outcomes, including death, occur in some individuals, 
particularly when administered by non-oral routes. Academic 
and occupational performance enhancement were the most 
commonly cited motivations for non-medical use of stimulants, 
but there is little evidence that academic performance is 
improved by non-medical use in individuals without ADHD 
(Faraone et al., 2020).  
190 The non-medical use of prescribed stimulants in individuals 
without ADHD is associated with lower educational attainment. 
A U.S. prospective study followed a nationally representative 
sample of over 8300 high school seniors from age 18 to age 35. 
Those who used prescription stimulants non-medically were 17 % 
less likely to earn a bachelor’s degree than those who had neither 
medical or non-medical use (McCabe et al., 2017).  
191 A retrospective study compared 4.4 million people dispensed 
ADHD medications with 6.1 million people dispensed asthma 
medications. Obtaining prescriptions from multiple prescribers 
or filling prescriptions at multiple pharmacies was highly corre-
lated with abuse, misuse, and diversion. These “shopping” be-
haviors were four times more frequent in the ADHD group than in 
the asthma group. Those dispensed stimulant medications were 
more than eight times as likely to engage in shopping behavior 
than those dispensed nonstimulants, but only one in 250 people 
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with stimulant prescriptions engaged in shopping behavior 
(Cepeda et al., 2014).  
192 A U.S. study of over 440,000 respondents found that use of illegal 
drugs or other non-medical use of prescription drugs preceded 
non-medical use of ADHD medication in more than three out of 
four cases (Sweeney et al., 2013).  
193 A study examined Swedish national pharmacy dispensing data for 
all 56,922 individuals who filled a methylphenidate prescription 
between 2010 and 2011. 4304 of the methylphenidate users (7.6 
%) overused medication as measured by dispensed prescriptions. 
Overuse was 17 times more frequent for ages 46–65 compared 
with ages 6− 12 year. It was also twice as frequent among those 
with previous alcohol and drug misuse (Bjerkeli et al., 2018).  
194 Large studies of calls to U.S. poison control centers related to 
ADHD medications find that intentional exposures, including 
suspected suicide and medication abuse and/or misuse is asso-
ciated with admission to critical care units and, rarely, death 
especially when snorted or injected (Faraone et al., 2019a; King 
et al., 2018). 
13. Which non-medication treatments are safe and effective for 
ADHD? 
Many non-medical treatments have been proposed for ADHD. Most 
of those offered on the Internet have not been tested or have been shown 
not to be effective. In this section, we distinguish between the effects of a 
treatment for ADHD symptoms and other benefits it may confer. Due to 
the way these therapies are implemented and recorded in the medical 
record, large scale naturalistic studies of longer-term outcomes are not 
possible. 
13.1. Behavioral and Cognitive-Behavioral Therapies 
Behavioral treatments for ADHD are diverse in nature and have a 
different content and focus depending on the age of the patient. For 
preschoolers and grade-school children, parents are trained to improve 
their method of disciplining and interacting with their children. For 
adolescents and adults, therapy helps patients improve their organiza-
tional skills. For some patients, teachers contribute to a program aimed 
at improving the child’s behavior. Some of these therapies focus on 
improving social behaviors and developing practical skills. In this sec-
tion, however, we focus only on the ability of such treatments to 
improve ADHD symptoms. Readers should keep in mind that the failure 
of a treatment to substantially improve ADHD symptoms does not mean 
it is not useful for other purposes.  
195 A meta-analysis found parent training for preschool children with 
ADHD to be associated with a moderate reduction in parent- 
reported ADHD symptoms (15 studies, few with active controls, 
over a thousand participants) and conduct problems (14 studies, 
few with active controls, over a thousand participants), but no 
significant results for independently assessed ADHD symptoms (6 
studies, 403 participants) and conduct problems (6 studies, 311 
participants). Independent assessments reported a small reduc-
tion in negative parenting (10 studies, 771 participants) 
(Rimestad et al., 2019).  
196 A meta-analysis of 19 studies of cognitive behavior therapy (CBT) 
for adults with ADHD included 896 participants. It found asso-
ciations with moderate improvements in self-reported ADHD 
symptoms and self-reported functioning. But when limited to the 
two studies with active controls and blind assessors (N = 244 
participants), it found only small improvements (Knouse et al., 
2017). In another meta-analysis of four studies with 160 patients 
with adult ADHD, CBT led to large to moderate improvements 
compared with waiting list controls. In three studies of 191 
patients CBT led to small to moderate improvements compared 
with active controls (Young et al., 2020).  
197 A meta-analysis of 32 studies with over two thousand participants 
found that cognitive training resulted in small to moderate im-
provements in executive functioning in preschoolers with ADHD 
(Scionti et al., 2019).  
198 A meta-analysis explored the effectiveness of meditation-based 
therapy. It found moderate reductions in ADHD symptoms in 
both children and adolescents (6 RCTs, 240 participants) and 
adults (6 RCTs, 339 participants), but half the studies did not use 
active controls. Removing studies with waiting list controls made 
results nonsignificant. The authors concluded “there is insuffi-
cient methodologically sound evidence to support the recom-
mendation of meditation-based therapies as an intervention 
aimed to target ADHD core symptoms or related neuropsycho-
logical dysfunctions in children/adolescents or adults with 
ADHD” (Zhang et al., 2018).  
199 A meta-analysis found that social skills training for youth with 
ADHD did not improve teacher-assessed social skills (11 studies, 
over 1200 youths), general behavior (8 studies, over 1000 
youths), or school performance and grades (5 studies, over 600 
youths) (Storebo et al., 2019).  
200 A meta-analysis of ten studies with 893 youths reported that 
organizational skills interventions led to moderate reductions in 
parent-reported inattention symptoms (Bikic et al., 2017). 
13.2. Computer-based cognitive training and neurofeedback  
201 A meta-analysis of five randomized controlled trials (RCTs) with 
263 participants exploring the efficacy of neurofeedback found a 
small reduction in inattention, but no significant reduction in 
hyperactivity-impulsivity or overall ADHD symptoms with rat-
ings by probably blinded evaluators (researchers measuring 
outcomes did not know if patients were receiving the active or 
control treatment) (Micoulaud-Franchi et al., 2014).  
202 The European ADHD Guidelines Group published meta-analyses 
of cognitive training and neurofeedback for youth. Probably 
blinded cognitive training studies with active controls (6 studies, 
287 youths) reported no significant reduction in ADHD symp-
toms. But they did find moderate improvements in verbal work-
ing memory (5 studies, 263 youths). There were no significant 
effects on academic outcomes in math and reading (95 studies, 
290 youths) (Cortese et al., 2015). Blinded neurofeedback studies 
with active/sham controls (6 studies, 251 participants) found no 
significant reduction in ADHD symptoms (Cortese et al., 2016a).  
203 A meta-analysis found that working memory training led to short- 
term improvements in both verbal working memory (21 studies, 
over 1300 participants) and visuospatial working memory (18 
studies, over 1000 participants), with “no convincing evidence 
that even such near-transfer effects are durable.” Moreover, most 
of the studies lacked active controls (Melby-Lervag and Hulme, 
2013). 
13.3. Supplements, diet, and exercise  
204 Omega-3 fatty acid supplementation was associated with small- 
to-medium improvements in ADHD symptoms in three meta- 
analyses (ten studies with 699 participants, 16 studies with 
1408 participants, 7 studies with 534 participants) (Bloch and 
Qawasmi, 2011; Chang et al., 2018; Hawkey and Nigg, 2014). 
Another meta-analysis, with 18 studies and 1640 participants, 
found tiny improvements (Puri and Martins, 2014).  
205 A meta-analysis found no evidence of any effect of omega-3 fatty 
acid supplements on parent-rated (5 studies, 650 children) or 
teacher-rated (3 studies, 598 children) emotional lability symp-
toms, or parent-rated (8 studies, 875 children) or teacher-rated (6 
S.V. Faraone et al.                                                                                                                                                                                                                              
Neuroscience and Biobehavioral Reviews 128 (2021) 789–818
806
studies, 805 children) oppositional symptoms in children with 
ADHD (Cooper et al., 2016).  
206 A meta-analysis of five double-blind crossover studies with 164 
participants found that restricting synthetic food colors from 
children’s diets was associated with a small reduction in ADHD 
symptoms (Nigg et al., 2012).  
207 A meta-analysis of ten studies (300 children) found exercise was 
associated with a moderate reduction in ADHD symptoms, but 
had no significant effect after adjusting for publication bias 
(Vysniauske et al., 2020). Another meta-analysis found no sig-
nificant effect of exercise on either hyperactivity/impulsivity (4 
studies, 227 participants) or inattention symptoms (6 studies, 277 
participants), but significant reductions in anxiety and depression 
(5 studies, 164 participants) (Zang, 2019).  
208 A nationwide population study using the Swedish Twin Register 
identified almost 18,000 twins who completed a web-based sur-
vey examining the relationship between inattention and hyper-
activity/impulsivity subtypes and dietary habits. The two 
subtypes of ADHD exhibited very similar associations. Both had 
significant associations with unhealthy diets. Both were more 
likely to be eating foods high in added sugar and neglecting fruits 
and vegetables while eating more meat and fats. After adjusting 
for degree of relatedness of twins (whether monozygotic or 
dizygotic) and controlling for the other ADHD subtype, the as-
sociations remained statistically significant for inattention, but 
diminished to negligible levels or became statistically nonsignif-
icant for hyperactivity/impulsivity. Even for persons with inat-
tention symptoms, adjusted correlations were small (never 
exceeding r = 0.10), with the strongest associations being for 
overall unhealthy eating habits and eating foods high in added 
sugar. Among over 700 pairs of monozygotic (“identical”) twins, 
it found small but robust associations between inattention 
symptoms and unhealthy eating habits, and especially with 
consumption of foods high in added sugar. For hyperactivity/ 
impulsivity symptoms, the association with unhealthy eating 
habits was weaker, and the association with consumption of 
foods high in added sugar became statistically insignificant (Li 
et al., 2020). 
14. Discussion 
This work has curated evidence-based statements about ADHD 
which paint a picture of the disorder that we summarize as follows: 
ADHD is a chronic disorder in which developmentally inappropriate 
symptoms of inattention and/or hyperactivity/impulsivity lead to 
impairments in many aspects of living. The disorder, which starts in 
childhood or early adolescence and is more common in boys than 
girls, affects 5.9 % of youth and 2.8 % of adults worldwide. There are 
multiple genetic and environmental risk factors that accumulate in 
various combinations to cause ADHD. These risk factors lead to 
subtle changes in multiple brain networks and in the cognitive, 
motivational, and emotional processes they control. People diag-
nosed with ADHD have an elevated risk for school failure, antisocial 
behavior, other psychiatric problems, somatic disorders, drug and 
alcohol abuse, accidental injuries, and premature death, including 
attempted and completed suicide. As a result, ADHD costs society 
hundreds of billions of dollars each year. Several medications are 
safe and effective for treating ADHD and for preventing many 
adverse outcomes. Non-medication treatments are available but, 
compared with medications, are less effective for reducing inatten-
tion, hyperactivity, and impulsivity. 
Despite this large body of evidence, we have much more to learn 
about the disorder and its various manifestations. Epidemiologic studies 
have taught us that ADHD occurs around the world, but we know little 
about how culture affects the expression of ADHD symptoms or the 
response to treatment. Because most research about ADHD is based on 
Caucasian and East Asian samples, we must be cautious in generalizing 
our assertions to other groups. In addition, far more research pertains to 
males than females. We also need to learn more about ADHD in older 
adults. Future research into ADHD should examine more diverse sam-
ples from a wider range of cultural contexts. 
We have learned much about the causes of ADHD but are only 
beginning to understand how genes and environment combine to cause 
the disorder and affect the brain to produce symptoms and impairments. 
Some of these causes may be shared with ADHD’s somatic comorbid-
ities. Examples include oxidative stress, inflammation, and insulin 
resistance. Future work should focus on biological and psychological 
causal mechanisms to find points of intervention that will improve the 
effectiveness of medical and non-medical treatments and, eventually, 
prevent onset of the disorder. Although the medications that treat ADHD 
are highly effective, we need better methods to prevent the misuse and 
diversion of these medications, especially among adolescents and young 
adults (Faraone et al., 2020). 
Many decades of research have led to a method of diagnosing ADHD 
that is highly valid as a predictor of treatment response, family history of 
ADHD, many clinical features, measures of brain structure and function, 
and adverse outcomes. Nevertheless, there are several new directions for 
diagnosis. One is to better understand the nature and causes of 
emotional symptoms in ADHD and whether these should be incorpo-
rated into diagnostic criteria (Faraone et al., 2019b). Another is to 
determine if and how mild or sub-threshold cases of ADHD should be 
diagnosed and treated (Kirova et al., 2019). Different trajectories of 
ADHD across the life-cycle need to be further investigated. 
Many researchers are trying to develop computerized or biological 
tests using information about the patient’s behavior, brain and/or ge-
netic makeup. The hope is that such tests will one day diagnose the 
disorder, predict a personalized approach to treatment, or assist clini-
cians in these areas. Others are working on methods that use the vast 
data available from medical records to predict which patients with 
ADHD are at greatest risk for adverse outcomes later in life. Such work 
may someday allow healthcare systems to allocate resources to the 
highest risk patients. 
Although we have good treatments for ADHD, even the best treat-
ments are only partially effective. The future of treatment for ADHD will 
include new medications currently in development and a stronger evi-
dence base for novel non-medication treatments for treating ADHD 
symptoms or associated impairments, such as trigeminal nerve stimu-
lation (McGough et al., 2019) and game-based treatments (Craven and 
Groom, 2015; Dovis et al., 2015). And more data are needed to improve 
existing non-medication treatments and to test the efficacy of traditional 
therapies such as acupuncture, yoga, and Ayurvedic therapies. Also, 
little is known about how the somatic disorders that co-occur with 
ADHD interact with treatments for ADHD and how the symptoms of the 
disorder affect somatic outcomes. We need to learn more about how 
duration of treatment affects outcomes over longer periods of time. 
We also know little about stigma and ADHD. Stigmatizing attitudes 
toward ADHD are common and may play a role in socially and clinically 
important outcomes. These negative attitudes affect patients at all stages 
of their life. Such attitudes have been documented among individuals at 
all ages and in all groups, including family, peers, teachers, clinicians, 
and even individuals with ADHD themselves (Lebowitz, 2016). 
Despite these and other gaps in our knowledge about ADHD, nearly 
two and a half centuries after the first textbook description of an ADHD- 
like syndrome, the statements about ADHD which we have curated, 
make us confident that the contemporary diagnosis of the disorder is a 
valid and useful category that can be used around the world to improve 
the lives of the many people who suffer from the disorder and its 
complications. 
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Lu, Y., Sjölander, A., Cederlöf, M., et al., 2017. Association between medication use and 
performance on higher education entrance tests in individuals with attention-deficit/ 
hyperactivity disorder. JAMA Psychiatry 74, 815–822. 
Lugo, J., Fadeuilhe, C., Gisbert, L., Setien, I., Delgado, M., Corrales, M., Richarte, V., 
Ramos-Quiroga, J.A., 2020. Sleep in adults with autism spectrum disorder and 
attention deficit/hyperactivity disorder: a systematic review and meta-analysis. Eur. 
Neuropsychopharmacol. 38, 1–24. 
Lukito, S., Norman, L., Carlisi, C., Radua, J., Hart, H., Simonoff, E., Rubia, K., 2020. 
Comparative meta-analyses of brain structural and functional abnormalities during 
cognitive control in attention-deficit/hyperactivity disorder and autism spectrum 
disorder. Psychol. Med. 50, 894–919. 
Maher, G.M., O’Keeffe, G.W., Kearney, P.M., Kenny, L.C., Dinan, T.G., Mattsson, M., 
Khashan, A.S., 2018. Association of hypertensive disorders of pregnancy with risk of 
neurodevelopmental disorders in offspring: a systematic review and meta-analysis. 
JAMA Psychiatry 75, 809–819. 
Maher, G.M., Dalman, C., O’Keeffe, G.W., Kearney, P.M., McCarthy, F.P., Kenny, L.C., 
Khashan, A.S., 2020. Association between preeclampsia and attention-deficit 
hyperactivity disorder: a population-based and sibling-matched cohort study. Acta 
Psychiatr. Scand. 142 (4), 275–283. 
Man, K.K., Chan, E.W., Coghill, D., Douglas, I., Ip, P., Leung, L.P., Tsui, M.S., Wong, W. 
H., Wong, I.C., 2015. Methylphenidate and the risk of trauma. Pediatrics 135, 40–48. 
Man, K.K., Coghill, D., Chan, E.W., Lau, W.C., Hollis, C., Liddle, E., Banaschewski, T., 
McCarthy, S., Neubert, A., Sayal, K., Ip, P., Wong, I.C., 2016. Methylphenidate and 
the risk of psychotic disorders and hallucinations in children and adolescents in a 
large health system. Transl. Psychiatry 6, e956. 
Man, K.K.C., Coghill, D., Chan, E.W., Lau, W.C.Y., Hollis, C., Liddle, E., Banaschewski, T., 
McCarthy, S., Neubert, A., Sayal, K., Ip, P., Schuemie, M.J., Sturkenboom, M., 
Sonuga-Barke, E., Buitelaar, J., Carucci, S., Zuddas, A., Kovshoff, H., Garas, P., 
Nagy, P., Inglis, S.K., Konrad, K., Hage, A., Rosenthal, E., Wong, I.C.K., 2017. 
Association of risk of suicide attempts with methylphenidate treatment. JAMA 
Psychiatry 74, 1048–1055. 
Maneeton, N., Maneeton, B., Woottiluk, P., Suttajit, S., Likhitsathian, S., Charnsil, C., 
Srisurapanont, M., 2015. Comparative efficacy, acceptability, and tolerability of 
dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis 
of randomized controlled trials. Neuropsychiatr. Dis. Treat. 11, 2943–2952. 
Martin, J., Taylor, M.J., Rydell, M., Riglin, L., Eyre, O., Lu, Y., Lundstrom, S., Larsson, H., 
Thapar, A., Lichtenstein, P., 2018. Sex-specific manifestation of genetic risk for 
attention deficit hyperactivity disorder in the general population. J. Child Psychol. 
Psychiatry 59, 908–916. 
Martinez-Badia, J., Martinez-Raga, J., 2015. Who says this is a modern disorder? The 
early history of attention deficit hyperactivity disorder. World J. Psychiatry 5, 
379–386. 
Marx, I., Hacker, T., Yu, X., Cortese, S., Sonuga-Barke, E., 2021. ADHD and the choice of 
small immediate over larger delayed rewards: a comparative meta-analysis of 
performance on simple choice-delay and temporal discounting paradigms. J. Atten. 
Disord. 25 (2), 171–187. 
McCabe, S.E., Veliz, P., Wilens, T.E., Schulenberg, J.E., 2017. Adolescents’ prescription 
stimulant use and adult functional outcomes: a national prospective study. J. Am. 
Acad. Child Adolesc. Psychiatry 56, 226–233 e224.  
McCarthy, S., Neubert, A., Man, K.K.C., Banaschewski, T., Buitelaar, J., Carucci, S., 
Coghill, D., Danckaerts, M., Falissard, B., Garas, P., Hage, A., Hollis, C., Inglis, S., 
Kovshoff, H., Liddle, E., Mechler, K., Nagy, P., Rosenthal, E., Schlack, R., Sonuga- 
Barke, E., Zuddas, A., Wong, I.C.K., 2018. Effects of long-term methylphenidate use 
on growth and blood pressure: results of the German Health Interview and 
Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry 18, 327. 
McCauley, H.L., Breslau, J.A., Saito, N., Miller, E., 2015. Psychiatric disorders prior to 
dating initiation and physical dating violence before age 21: findings from the 
National Comorbidity Survey Replication (NCS-R). Soc. Psychiatry Psychiatr. 
Epidemiol. 50, 1357–1365. 
McGough, J.J., Sturm, A., Cowen, J., Tung, K., Salgari, G.C., Leuchter, A.F., Cook, I.A., 
Sugar, C.A., Loo, S.K., 2019. Double-blind, sham-controlled, pilot study of trigeminal 
nerve stimulation for attention-deficit/hyperactivity disorder. J. Am. Acad. Child 
Adolesc. Psychiatry 58, 403–411 e403.  
McLeod, J.D., Fettes, D.L., Jensen, P.S., Pescosolido, B.A., Martin, J.K., 2007. Public 
knowledge, beliefs, and treatment preferences concerning attention-deficit 
hyperactivity disorder. Psychiatr. Serv. 58, 626–631. 
Melby-Lervag, M., Hulme, C., 2013. Is working memory training effective? A meta- 
analytic review. Dev. Psychol. 49, 270–291. 
Micoulaud-Franchi, J.A., Geoffroy, P.A., Fond, G., Lopez, R., Bioulac, S., Philip, P., 2014. 
EEG neurofeedback treatments in children with ADHD: an updated meta-analysis of 
randomized controlled trials. Front. Hum. Neurosci. 8, 906. 
Mohr-Jensen, C., Muller Bisgaard, C., Boldsen, S.K., Steinhausen, H.C., 2019. Attention- 
Deficit/Hyperactivity disorder in childhood and adolescence and the risk of crime in 
young adulthood in a Danish nationwide study. J. Am. Acad. Child Adolesc. 
Psychiatry 58, 443–452. 
Momany, A.M., Kamradt, J.M., Nikolas, M.A., 2018. A meta-analysis of the association 
between birth weight and attention deficit hyperactivity disorder. J. Abnorm. Child 
Psychol. 46, 1409–1426. 
Montes, G., Halterman, J.S., 2007. Bullying among children with autism and the 
influence of comorbidity with ADHD: a population-based study. Ambul. Pediatr. 7, 
253–257. 
Morris, H.H., Escoll, P.J., Wexler, R., 1956. Aggressive behavior disorders of childhood: a 
follow-up study. Am. J. Psychiatry 112, 991–997. 
Mueller, A.K., Fuermaier, A.B., Koerts, J., Tucha, L., 2012. Stigma in attention deficit 
hyperactivity disorder. Atten. Defic. Hyperact. Disord. 4, 101–114. 
National Collaborating Centre for Mental Health, 2018. Attention Deficit Hyperactivity 
Disorder: Diagnosis and Management of ADHD in Children, Young People and 
Adults. British Psychological Society. 
Copyright (c) National Institute for Health and Care Excellence 2018, Leicester (UK). 
National Institute for Health Care and Excellence, 2018b. Attention Defificit 
Hyperactivity Disorder: Diagnosis and Management. March 14, 2018 ed. National 
Institute for Health Care and Excellence, United Kingdom.  
Nazar, B.P., Bernardes, C., Peachey, G., Sergeant, J., Mattos, P., Treasure, J., 2016. The 
risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: a 
systematic review and meta-analysis. Int. J. Eat. Disord. 49, 1045–1057. 
Nelson, L.D., Guskiewicz, K.M., Marshall, S.W., Hammeke, T., Barr, W., Randolph, C., 
McCrea, M.A., 2016. Multiple self-reported concussions are more prevalent in 
athletes with ADHD and learning disability. Clin. J. Sport Med. 26, 120–127. 
Neumarker, K.J., 2005. The Kramer-Pollnow syndrome: a contribution on the life and 
work of Franz Kramer and Hans Pollnow. Hist. Psychiatry 16, 435–451. 
Nielsen, P.R., Benros, M.E., Dalsgaard, S., 2017. Associations between autoimmune 
diseases and attention-deficit/hyperactivity disorder: a nationwide study. J. Am. 
Acad. Child Adolesc. Psychiatry 56, 234–240 e231.  
Nigg, J.T., Lewis, K., Edinger, T., Falk, M., 2012. Meta-analysis of attention-deficit/ 
hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, 
restriction diet, and synthetic food color additives. J. Am. Acad. Child Adolesc. 
Psychiatry 51, 86–97 e88.  
Nigg, J.T., Johnstone, J.M., Musser, E.D., Long, H.G., Willoughby, M.T., Shannon, J., 
2016. Attention-deficit/hyperactivity disorder (ADHD) and being overweight/ 
obesity: new data and meta-analysis. Clin. Psychol. Rev. 43, 67–79. 
Nilsen, F.M., Tulve, N.S., 2020. A systematic review and meta-analysis examining the 
interrelationships between chemical and non-chemical stressors and inherent 
characteristics in children with ADHD. Environ. Res. 180, 108884. 
Norman, L.J., Carlisi, C., Lukito, S., Hart, H., Mataix-Cols, D., Radua, J., Rubia, K., 2016. 
Structural and functional brain abnormalities in attention-deficit/hyperactivity 
disorder and obsessive-compulsive disorder: a comparative meta-analysis. JAMA 
Psychiatry 73, 815–825. 
O’Neal, P., Robins, L.N., 1958. Childhood patterns predictive of adult schizophrenia: a 
30-year follow-up study. Am. J. Psychiatry 115, 385–391. 
Obel, C., Zhu, J.L., Olsen, J., Breining, S., Li, J., Gronborg, T.K., Gissler, M., Rutter, M., 
2016. The risk of attention deficit hyperactivity disorder in children exposed to 
maternal smoking during pregnancy - a re-examination using a sibling design. 
J. Child Psychol. Psychiatry 57, 532–537. 
Ostergaard, S.D., Larsen, J.T., Dalsgaard, S., Wilens, T.E., Mortensen, P.B., Agerbo, E., 
Mors, O., Petersen, L., 2016. Predicting ADHD by assessment of Rutter’s indicators of 
adversity in infancy. PLoS One 11, e0157352. 
Ostergaard, S.D., Dalsgaard, S., Faraone, S.V., Munk-Olsen, T., Laursen, T.M., 2017. 
Teenage parenthood and birth rates for individuals with and without attention- 
S.V. Faraone et al.                                                                                                                                                                                                                              
Neuroscience and Biobehavioral Reviews 128 (2021) 789–818
816
deficit/hyperactivity disorder: a nationwide cohort study. J. Am. Acad. Child 
Adolesc. Psychiatry 56, 578–584 e573.  
Ouyang, L., Fang, X., Mercy, J., Perou, R., Grosse, S.D., 2008. Attention-deficit/ 
hyperactivity disorder symptoms and child maltreatment: a population-based study. 
J. Pediatr. 153, 851–856. 
Palmer, E.D., Finger, S., 2001. An early description of ADHD (Inattentive subtype): Dr 
Alexander Crichton and mental restlessness (1798). Child Psychol. Psychiatry Rev. 6, 
66–73. 
Pan, Y.Q., Qiao, L., Xue, X.D., Fu, J.H., 2015. Association between ANKK1 (rs1800497) 
polymorphism of DRD2 gene and attention deficit hyperactivity disorder: a meta- 
analysis. Neurosci. Lett. 590, 101–105. 
Park, J., Sohn, J.H., Cho, S.J., Seo, H.Y., Hwang, I.U., Hong, Y.C., Kim, K.N., 2020. 
Association between short-term air pollution exposure and attention-deficit/ 
hyperactivity disorder-related hospital admissions among adolescents: a nationwide 
time-series study. Environ. Pollut. 266, 115369. 
Patros, C.H., Alderson, R.M., Kasper, L.J., Tarle, S.J., Lea, S.E., Hudec, K.L., 2016. 
Choice-impulsivity in children and adolescents with attention-deficit/hyperactivity 
disorder (ADHD): a meta-analytic review. Clin. Psychol. Rev. 43, 162–174. 
Patros, C.H.G., Tarle, S.J., Alderson, R.M., Lea, S.E., Arrington, E.F., 2019. Planning 
deficits in children with attention-deficit/hyperactivity disorder (ADHD): a meta- 
analytic review of tower task performance. Neuropsychology 33, 425–444. 
Pauli-Pott, U., Mann, C., Becker, K., 2020. Do cognitive interventions for preschoolers 
improve executive functions and reduce ADHD and externalizing symptoms? A 
meta-analysis of randomized controlled trials. Eur. Child Adolesc. Psychiatry. 
https://doi.org/10.1007/s00787-020-01627-z. 
Pearl, P.L., Weiss, R.E., Stein, M.A., 2001. Medical mimics. Medical and neurological 
conditions simulating ADHD. Ann. N. Y. Acad. Sci. 931, 97–112. 
Pettersson, E., Lichtenstein, P., Larsson, H., Song, J., Agrawal, A., Borglum, A.D., 
Bulik, C.M., Daly, M.J., Davis, L.K., Demontis, D., Edenberg, H.J., Grove, J., 
Gelernter, J., Neale, B.M., Pardinas, A.F., Stahl, E., Walters, J.T.R., Walters, R., 
Sullivan, P.F., Posthuma, D., Polderman, T.J.C., 2019. Genetic influences on eight 
psychiatric disorders based on family data of 4 408 646 full and half-siblings, and 
genetic data of 333 748 cases and controls. Psychol. Med. 49, 1166–1173. 
Pievsky, M.A., McGrath, R.E., 2018. The neurocognitive profile of attention-deficit/ 
hyperactivity disorder: a review of meta-analyses. Arch. Clin. Neuropsychol. 33, 
143–157. 
Pliszka, S., 2007. Practice parameter for the assessment and treatment of children and 
adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child 
Adolesc. Psychiatry 46, 894–921. 
Pohlabeln, H., Rach, S., De Henauw, S., Eiben, G., Gwozdz, W., Hadjigeorgiou, C., 
Molnar, D., Moreno, L.A., Russo, P., Veidebaum, T., Pigeot, I., 2017. Further 
evidence for the role of pregnancy-induced hypertension and other early life 
influences in the development of ADHD: results from the IDEFICS study. Eur. Child 
Adolesc. Psychiatry 26, 957–967. 
Polanczyk, G.V., Willcutt, E.G., Salum, G.A., Kieling, C., Rohde, L.A., 2014. ADHD 
prevalence estimates across three decades: an updated systematic review and meta- 
regression analysis. Int. J. Epidemiol. 43, 434–442. 
Pozzi, M., Carnovale, C., Peeters, G., Gentili, M., Antoniazzi, S., Radice, S., Clementi, E., 
Nobile, M., 2018. Adverse drug events related to mood and emotion in paediatric 
patients treated for ADHD: a meta-analysis. J. Affect. Disord. 238, 161–178. 
Pringsheim, T., Hirsch, L., Gardner, D., Gorman, D.A., 2015. The pharmacological 
management of oppositional behaviour, conduct problems, and aggression in 
children and adolescents with attention-deficit hyperactivity disorder, oppositional 
defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 
1: psychostimulants, alpha-2 agonists, and atomoxetine. Can. J. Psychiatry 60, 
42–51. 
Puri, B.K., Martins, J.G., 2014. Which polyunsaturated fatty acids are active in children 
with attention-deficit hyperactivity disorder receiving PUFA supplementation? A 
fatty acid validated meta-regression analysis of randomized controlled trials. 
Prostaglandins Leukot. Essent. Fatty Acids 90, 179–189. 
Ramos, A.A., Hamdan, A.C., Machado, L., 2020. A meta-analysis on verbal working 
memory in children and adolescents with ADHD. Clin. Neuropsychol. 34, 873–898. 
Rimestad, M.L., Lambek, R., Zacher Christiansen, H., Hougaard, E., 2019. Short- and 
long-term effects of parent training for preschool children with or at risk of ADHD: a 
systematic review and meta-analysis. J. Atten. Disord. 23, 423–434. 
Robins, E., Guze, S.B., 1970. Establishment of diagnostic validity in psychiatric illness: its 
application to schizophrenia. Am. J. Psychiatry 126, 983–987. 
Rommelse, N., Antshel, K., Smeets, S., Greven, C., Hoogeveen, L., Faraone, S.V., 
Hartman, C.A., 2017. High intelligence and the risk of ADHD and other 
psychopathology. Br. J. Psychiatry 211, 359–364. 
Ros, R., Graziano, P.A., 2018. Social functioning in children with or at risk for attention 
deficit/hyperactivity disorder: a meta-analytic review. J. Clin. Child Adolesc. 
Psychol. 47, 213–235. 
Rosenthal, R., Rosnow, R.L., 1984. Essentials of Behavioral Research: Methods and Data 
Analysis, 361. 
Rubia, K., Alegria, A.A., Cubillo, A.I., Smith, A.B., Brammer, M.J., Radua, J., 2014. 
Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a 
systematic review and meta-analysis. Biol. Psychiatry 76, 616–628. 
Ruiz-Goikoetxea, M., Cortese, S., Aznarez-Sanado, M., Magallon, S., Alvarez Zallo, N., 
Luis, E.O., de Castro-Manglano, P., Soutullo, C., Arrondo, G., 2018a. Risk of 
unintentional injuries in children and adolescents with ADHD and the impact of 
ADHD medications: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 
84, 63–71. 
Ruiz-Goikoetxea, M., Cortese, S., Magallon, S., Aznarez-Sanado, M., Alvarez Zallo, N., 
Luis, E.O., de Castro-Manglano, P., Soutullo, C., Arrondo, G., 2018b. Risk of 
poisoning in children and adolescents with ADHD: a systematic review and meta- 
analysis. Sci. Rep. 8, 7584. 
Rydell, M., Lundstrom, S., Gillberg, C., Lichtenstein, P., Larsson, H., 2018. Has the 
attention deficit hyperactivity disorder phenotype become more common in children 
between 2004 and 2014? Trends over 10 years from a Swedish general population 
sample. J. Child Psychol. Psychiatry 59, 863–871. 
Samea, F., Soluki, S., Nejati, V., Zarei, M., Cortese, S., Eickhoff, S.B., Tahmasian, M., 
Eickhoff, C.R., 2019. Brain alterations in children/adolescents with ADHD revisited: 
a neuroimaging meta-analysis of 96 structural and functional studies. Neurosci. 
Biobehav. Rev. 
Sanchez, C., Barry, C., Sabhlok, A., Russell, K., Majors, A., Kollins, S., Fuemmeler, B., 
2018. Maternal pre-pregnancy obesity and child neurodevelopmental outcomes: a 
meta-analysis. Obes. Rev. 19, 464–484. 
Satterstrom, F.K., Walters, R.K., Singh, T., Wigdor, E.M., Lescai, F., Demontis, D., 
Kosmicki, J.A., Grove, J., Stevens, C., Bybjerg-Grauholm, J., Baekvad-Hansen, M., 
Palmer, D.S., Maller, J.B., Nordentoft, M., Mors, O., Robinson, E.B., Hougaard, D.M., 
Werge, T.M., Bo Mortensen, P., Neale, B.M., Borglum, A.D., Daly, M.J., 2019. Autism 
spectrum disorder and attention deficit hyperactivity disorder have a similar burden 
of rare protein-truncating variants. Nat. Neurosci. 22, 1961–1965. 
Schab, D.W., Trinh, N.H., 2004. Do artificial food colors promote hyperactivity in 
children with hyperactive syndromes? A meta-analysis of double-blind placebo- 
controlled trials. J. Dev. Behav. Pediatr. 25, 423–434. 
Schoechlin, C., Engel, R.R., 2005. Neuropsychological performance in adult attention- 
deficit hyperactivity disorder: meta-analysis of empirical data. Arch. Clin. 
Neuropsychol. 20, 727–744. 
Schoeman, R., Liebenberg, R., 2017. The South African Society of Psychiatrists/ 
Psychiatry Management Group management guidelines for adult attention-deficit/ 
hyperactivity disorder. S. Afr. J. Psychiatr. 23, 1060. 
Schoenfelder, E.N., Faraone, S.V., Kollins, S.H., 2014. Stimulant treatment of ADHD and 
cigarette smoking: a meta-analysis. Pediatrics 133, 1070–1080. 
Schwartz, S., Correll, C.U., 2014. Efficacy and safety of atomoxetine in children and 
adolescents with attention-deficit/hyperactivity disorder: results from a 
comprehensive meta-analysis and metaregression. J. Am. Acad. Child Adolesc. 
Psychiatry 53, 174–187. 
Scionti, N., Cavallero, M., Zogmaister, C., Marzocchi, G.M., 2019. Is cognitive training 
effective for improving executive functions in preschoolers? A systematic review and 
meta-analysis. Front. Psychol. 10, 2812. 
Sedky, K., Bennett, D.S., Carvalho, K.S., 2014. Attention deficit hyperactivity disorder 
and sleep disordered breathing in pediatric populations: a meta-analysis. Sleep Med. 
Rev. 18, 349–356. 
Seixas, M., Weiss, M., Muller, U., 2012. Systematic review of national and international 
guidelines on attention-deficit hyperactivity disorder. J. Psychopharmacol. 26, 
753–765. 
Septier, M., Stordeur, C., Zhang, J., Delorme, R., Cortese, S., 2019. Association between 
suicidal spectrum behaviors and attention-deficit/hyperactivity disorder: a 
systematic review and meta-analysis. Neurosci. Biobehav. Rev. 103, 109–118. 
Shih, P., Huang, C.C., Pan, S.C., Chiang, T.L., Guo, Y.L., 2020. Hyperactivity disorder in 
children related to traffic-based air pollution during pregnancy. Environ. Res. 188, 
109588. 
Simon, V., Czobor, P., Balint, S., Meszaros, A., Bitter, I., 2009. Prevalence and correlates 
of adult attention-deficit hyperactivity disorder: meta-analysis. Br. J. Psychiatry 194, 
204–211. 
Skoglund, C., Chen, Q., D’Onofrio, B.M., Lichtenstein, P., Larsson, H., 2014. Familial 
confounding of the association between maternal smoking during pregnancy and 
ADHD in offspring. J. Child Psychol. Psychiatry 55, 61–68. 
Skoglund, C., Kopp Kallner, H., Skalkidou, A., Wikstrom, A.K., Lundin, C., Hesselman, S., 
Wikman, A., Sundstrom Poromaa, I., 2019. Association of attention-deficit/ 
hyperactivity disorder with teenage birth among women and girls in Sweden. JAMA 
Netw. Open 2, e1912463. 
Solberg, B.S., Halmoy, A., Engeland, A., Igland, J., Haavik, J., Klungsoyr, K., 2018. 
Gender differences in psychiatric comorbidity: a population-based study of 40 000 
adults with attention deficit hyperactivity disorder. Acta Psychiatr. Scand. 137, 
176–186. 
Solmi, M., Fornaro, M., Ostinelli, E.G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., 
Fusar-Poli, P., Correll, C.U., 2020. Safety of 80 antidepressants, antipsychotics, anti- 
attention-deficit/hyperactivity medications and mood stabilizers in children and 
adolescents with psychiatric disorders: a large scale systematic meta-review of 78 
adverse effects. World Psychiatry 19, 214–232. 
Song, M., Dieckmann, N.F., Nigg, J.T., 2019. Addressing discrepancies between ADHD 
prevalence and case identification estimates among U.S. children utilizing NSCH 
2007–2012. J. Atten. Disord. 23, 1691–1702. 
Spencer, T.J., Brown, A., Seidman, L.J., Valera, E.M., Makris, N., Lomedico, A., 
Faraone, S.V., Biederman, J., 2013. Effect of psychostimulants on brain structure and 
function in ADHD: a qualitative literature review of magnetic resonance imaging- 
based neuroimaging studies. J. Clin. Psychiatry 74, 902–917. 
Stein, M.A., 2008. Medical mimics and differential diagnosis in adult ADHD. CNS Spectr. 
13, 14–16. 
Still, G., 1902a. The Goulstonian lectures on some abnormal physical conditions in 
children. Lecture 1. Lancet 1008–0102 (1077–1082), 1163–1168. 
Still, G., 1902b. The Goulstonian lectures on some abnormal psychical conditions in 
children. Lecture II. Lancet 1, 1077–1082. 
Still, G., 1902c. The Goulstonian lectures on some abnormal psychical conditions in 
children. Lecture III. Lancet 1, 1163–1168. 
Stojanovski, S., Felsky, D., Viviano, J.D., Shahab, S., Bangali, R., Burton, C.L., 
Devenyi, G.A., O’Donnell, L.J., Szatmari, P., Chakravarty, M.M., Ameis, S., 
Schachar, R., Voineskos, A.N., Wheeler, A.L., 2019. Polygenic risk and neural 
S.V. Faraone et al.                                                                                                                                                                                                                              
Neuroscience and Biobehavioral Reviews 128 (2021) 789–818
817
substrates of attention-deficit/hyperactivity disorder symptoms in youths with a 
history of mild traumatic brain injury. Biol. Psychiatry 85, 408–416. 
Storebo, O.J., Elmose Andersen, M., Skoog, M., Joost Hansen, S., Simonsen, E., 
Pedersen, N., Tendal, B., Callesen, H.E., Faltinsen, E., Gluud, C., 2019. Social skills 
training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 
years. Cochrane Database Syst. Rev. 6, Cd008223. 
Storebø, O.J., Ramstad, E., Krogh, H.B., Nilausen, T.D., Skoog, M., Holmskov, M., 
Rosendal, S., Groth, C., Magnusson, F.L., Moreira-Maia, C.R., Gillies, D., Buch 
Rasmussen, K., Gauci, D., Zwi, M., Kirubakaran, R., Forsbøl, B., Simonsen, E., 
Gluud, C., 2015. Methylphenidate for children and adolescents with attention deficit 
hyperactivity disorder (ADHD). Cochrane Database Syst. Rev., Cd009885 
Strine, T.W., Lesesne, C.A., Okoro, C.A., McGuire, L.C., Chapman, D.P., Balluz, L.S., 
Mokdad, A.H., 2006. Emotional and behavioral difficulties and impairments in 
everyday functioning among children with a history of attention-deficit/ 
hyperactivity disorder. Prev. Chronic Dis. 3, A52. 
Su, C.C., Tsai, C.Y., Tsai, T.H., Tsai, I.J., 2019. Incidence and risk of attention-deficit 
hyperactivity disorder in children with amblyopia: a nationwide cohort study. 
Graefes Arch. Clin. Exp. Ophthalmol. 47, 259–264. 
Sucksdorff, M., Lehtonen, L., Chudal, R., Suominen, A., Joelsson, P., Gissler, M., 
Sourander, A., 2015. Preterm birth and poor fetal growth as risk factors of attention- 
deficit/ hyperactivity disorder. Pediatrics 136, e599–608. 
Sucksdorff, M., Brown, A.S., Chudal, R., Surcel, H.M., Hinkka-Yli-Salomaki, S., Cheslack- 
Postava, K., Gyllenberg, D., Sourander, A., 2021. Maternal vitamin D levels and the 
risk of offspring attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. 
Psychiatry 60 (1), P142–151.e2. 
Sun, C.K., Tseng, P.T., Wu, C.K., Li, D.J., Chen, T.Y., Stubbs, B., Carvalho, A.F., Chen, Y. 
W., Lin, P.Y., Cheng, Y.S., Wu, M.K., 2019a. Therapeutic effects of methylphenidate 
for attention-deficit/hyperactivity disorder in children with borderline intellectual 
functioning or intellectual disability: a systematic review and meta-analysis. Sci. 
Rep. 9, 15908. 
Sun, S., Kuja-Halkola, R., Faraone, S.V., D’Onofrio, B.M., Dalsgaard, S., Chang, Z., 
Larsson, H., 2019b. Association of psychiatric comorbidity with the risk of 
premature death among children and adults with attention-deficit/hyperactivity 
disorder. JAMA Psychiatry 76, 1141–1149. 
Sundquist, J., Ohlsson, H., Sundquist, K., Kendler, K.S., 2015. Attention-deficit/ 
hyperactivity disorder and risk for drug use disorder: a population-based follow-up 
and co-relative study. Psychol. Med. 45, 977–983. 
Sweeney, C.T., Sembower, M.A., Ertischek, M.D., Shiffman, S., Schnoll, S.H., 2013. 
Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug 
abuse. J. Addict. Dis. 32, 1–10. 
Swensen, A.R., Birnbaum, H.G., Secnik, K., Marynchenko, M., Greenberg, P., Claxton, A., 
2003. Attention-deficit/hyperactivity disorder: increased costs for patients and their 
families. J. Am. Acad. Child Adolesc. Psychiatry 42, 1415–1423. 
Tamminga, H.G., Reneman, L., Huizenga, H.M., Geurts, H.M., 2016. Effects of 
methylphenidate on executive functioning in attention-deficit/hyperactivity 
disorder across the lifespan: a meta-regression analysis. Psychol. Med. 46, 
1791–1807. 
Taylor, E., 2011. Antecedents of ADHD: a historical account of diagnostic concepts. 
Atten. Defic. Hyperact. Disord. 3, 69–75. 
Taylor, E., Dopfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., 
Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., Steinhausen, H.C., 
Zuddas, A., 2004. European clinical guidelines for hyperkinetic disorder-first 
upgrade. Eur. Child Adolesc. Psychiatry 13, i7–i30. 
Taylor, M.J., Martin, J., Lu, Y., Brikell, I., Lundstrom, S., Larsson, H., Lichtenstein, P., 
2019. Association of genetic risk factors for psychiatric disorders and traits of these 
disorders in a Swedish population twin sample. JAMA Psychiatry 76, 280–289. 
Thome, J., Ehlis, A.C., Fallgatter, A.J., Krauel, K., Lange, K.W., Riederer, P., 
Romanos, M., Taurines, R., Tucha, O., Uzbekov, M., Gerlach, M., 2012. Biomarkers 
for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the 
WFSBP task force on biological markers and the World Federation of ADHD. World J. 
Biol. Psychiatry 13, 379–400. 
Tseng, P.T., Cheng, Y.S., Yen, C.F., Chen, Y.W., Stubbs, B., Whiteley, P., Carvalho, A.F., 
Li, D.J., Chen, T.Y., Yang, W.C., Tang, C.H., Chu, C.S., Yang, W.C., Liang, H.Y., 
Wu, C.K., Lin, P.Y., 2018. Peripheral iron levels in children with attention-deficit 
hyperactivity disorder: a systematic review and meta-analysis. Sci. Rep. 8, 788. 
Tseng, J.J., Lin, C.H., Lin, M.C., 2020. Long-term outcomes of pediatric enterovirus 
infection in Taiwan: a population-based cohort study. Front. Pediatr. 8, 285. 
Tsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., 
Iida, J., Saito, T., 2020. Effect of continuing and discontinuing medications on 
quality of life after symptomatic remission in attention-deficit/hyperactivity 
disorder: a systematic review and meta-analysis. J. Clin. Psychiatry 81, 19r13015. 
Tung, I., Li, J.J., Meza, J.I., Jezior, K.L., Kianmahd, J.S., Hentschel, P.G., O’Neil, P.M., 
Lee, S.S., 2016. Patterns of comorbidity among girls with ADHD: a meta-analysis. 
Pediatrics 138, e20160430. 
Tylee, D.S., Sun, J., Hess, J.L., Tahir, M.A., Sharma, E., Malik, R., Worrall, B.B., Levine, A. 
J., Martinson, J.J., Nejentsev, S., Speed, D., Fischer, A., Mick, E., Walker, B.R., 
Crawford, A., Grant, S.F.A., Polychronakos, C., Bradfield, J.P., Sleiman, P.M.A., 
Hakonarson, H., Ellinghaus, E., Elder, J.T., Tsoi, L.C., Trembath, R.C., Barker, J.N., 
Franke, A., Dehghan, A., Team, a.M.R., Consortium, I.W.G.o.t.C, Consortium, M.C.o. 
t.I.S.G, Registry, N.T., Group, n.W., Consortum, O.C.a.T.S.W.G.o.t.P.G, Faraone, S.V., 
Glatt, S.J., 2018. Genetic correlations among psychiatric and immune-related 
phenotypes based on genome-wide association data. Am. J. Med. Genet. B 
Neuropsychiatr. Genet. 177, 641–657. 
Tzeng, N.S., Chung, C.H., Lin, F.H., Yeh, C.B., Huang, S.Y., Lu, R.B., Chang, H.A., Kao, Y. 
C., Yeh, H.W., Chiang, W.S., Chou, Y.C., Tsao, C.H., Wu, Y.F., Chien, W.C., 2019. 
Risk of dementia in adults with ADHD: a nationwide, population-based cohort study 
in Taiwan. J. Atten. Disord. 23, 995–1006. 
Vaa, T., 2014. ADHD and relative risk of accidents in road traffic: a meta-analysis. Accid. 
Anal. Prev. 62, 415–425. 
van der Schans, J., Aikman, B., de Vries, T.W., Hoekstra, P.J., Hak, E., 2017. Association 
between attention-deficit/hyperactivity disorder and asthma among adults: a case- 
control study. Chest 151, 1406–1407. 
van Hulzen, K.J.E., Scholz, C.J., Franke, B., Ripke, S., Klein, M., McQuillin, A., Sonuga- 
Barke, E.J., Group, P.A.W., Kelsoe, J.R., Landen, M., Andreassen, O.A., Group, P.G.C. 
B.D.W, Lesch, K.P., Weber, H., Faraone, S.V., Arias-Vasquez, A., Reif, A., 2017. 
Genetic overlap between attention-deficit/hyperactivity disorder and bipolar 
disorder: evidence from genome-wide association study meta-analysis. Biol. 
Psychiatry 82, 634–641. 
Vidal Perera, A., 1907. Compendio de psiquiatría infantil, 1st ed. Librería del Magisterio, 
Barcelona.  
Vink, J.M., Schellekens, A., 2018. Relating addiction and psychiatric disorders. Science 
361, 1323–1324. 
Vysniauske, R., Verburgh, L., Oosterlaan, J., Molendijk, M.L., 2020. The effects of 
physical exercise on functional outcomes in the treatment of ADHD: a meta-analysis. 
J. Atten. Disord. 24, 644–654. 
Wang, Y., Huang, L., Zhang, L., Qu, Y., Mu, D., 2017. Iron status in attention-deficit/ 
hyperactivity disorder: a systematic review and meta-analysis. PLoS One 12, 
e0169145. 
Wang, L.J., Lee, S.Y., Chou, W.J., Lee, M.J., Tsai, C.S., Lee, T.L., Yang, C.J., Yang, K.C., 
Chen, C.K., Shyu, Y.C., 2019. Testicular function after long-term methylphenidate 
treatment in boys with attention-deficit/hyperactivity disorder. J. Child Adolesc. 
Psychopharmacol. 29, 433–438. 
Wang, H., Li, F., Miao, M., Yu, Y., Ji, H., Liu, H., Huang, R., Obel, C., Zhang, J., Li, J., 
2020. Maternal spontaneous abortion and the risk of attention-deficit/hyperactivity 
disorder in offspring: a population-based cohort study. Hum. Reprod. 35, 
1211–1221. 
Weikard, M.A., 1799. Der philosophische Arzt. 3 Philosophische Arzeneykunst oder von 
Gebrechen der Sensationen, des Verstandes, und des Willens / von M.A. Weikard. 
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